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ABSTRACT 
 
Anne F. Rositch 
Human papillomavirus type competition and the associations between HPV types and future 
HPV acquisition in men 
(Under the direction of Jennifer S. Smith) 
 
Infection with human papillomavirus (HPV) is the primary cause of cervical cancer 
and other anogenital cancers.  Multiple HPV infections have been detected in up to 70% of 
HPV infected men, yet there are no data on the association between HPV types in men, 
which may impact the type-specific efficacy of HPV vaccination through HPV type 
competition and replacement.   
In a cohort of uncircumcised, human immunodeficiency virus (HIV)-seronegative 
men aged 17–28 years from Kisumu, Kenya, we assessed the associations between HPV 
types at baseline (N=2,702) using semi-Bayesian multivariate logistic regression.  In a 
prospective analysis (N=1,064) we used parametric survival models to compare rates of 
acquisition of HPV infections among men infected and uninfected with vaccine-relevant 
types HPV-16, 18, 31, 45, 6, and 11 at baseline.   
Half of all men were HPV positive at baseline, of whom 57% had multiple HPV 
infections.  In the cross-sectional analysis, HPV types 31, 39, 56, 58, and 59 were positively 
associated with both vaccine types HPV-16 and 18 (two-sided p-value <0.05); no negative 
associations between individual HPV types were observed.   
Over 2,462 person-years of follow-up, 2,233 incident HPV infections were detected.  
Men with HPV-18, 31, 45, or 11, but not HPV-16 or 6, had higher rates of any-HPV and 
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high-risk (HR) HPV acquisition compared to men without each HPV type at baseline.  
Relative rates of acquisition of individual HR-HPV types varied by baseline HPV type; 
however, we did not observe a clear pattern of HPV acquisition by degree of phylogenetic 
relatedness to the baseline infection. 
Except for HPV-39 acquisition among men with HPV-6 (aHR: 0.1 (0.0, 0.8)), there 
was no evidence of negative associations between HPV types or reduced HPV acquisition 
among men with baseline infections that indicate a strong potential for HPV type 
competition.  To better understand the potential for changes in the HPV type distribution 
following HPV vaccination, future studies that monitor HPV type distributions in pre- and 
post-vaccinated populations are needed. 
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Human papillomavirus infection 
Oncogenic human papillomavirus (HPV) infection is one of the most prevalent 
sexually transmitted infections (STI) worldwide and is a necessary cause of invasive cervical 
cancer[1-3].  It is responsible for other anogenital cancers, including vaginal and vulvar 
cancer in women, and anal and penile carcinoma in men.  There are over 130 types of HPV, 
40 of which infect the anogenital tract of men and women.  Fourteen types of HPV are 
considered oncogenic or high-risk (HR) HPV types because they are found in invasive 
cervical cancer biopsy specimens and laboratory data have shown their oncogenic potential.  
HR-HPV infection is considered a necessary cause of cervical precancer and invasive 
cervical cancer among women[1, 3, 4].  HR-HPV types include 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, and 68.  Types classified as low oncogenic risk (LR) HPV include 6, 11, 
26, 30, 32, 34, 40, 42, 43, 44, 53, 54 55, 57, 61, 64, 67, 69, 70, 71 (equivalent to CP8061), 
72, 73, 81 (equivalent to CP8304), 82 (IS39 and MM4 subtypes), 83 (equivalent to MM7), 84 
(equivalent to MM8), 85 (cand85), 86, 89 (cand89 equivalent to CP6108), and JC9710.  
There are currently two FDA-approved HPV vaccines that provide type-specific 
protection against HPV infection in both men and women.  Merck produces a quadrivalent 
HPV vaccine that protects against high-risk HPV types 16 and 18, and against LR-HPV types 
6 and 11[5-7].  Nearly 70% of cases of cervical cancer have been attributed to infection with 
HPV types 16 and 18 and types 6 and 11 are responsible for the majority (~90%) of genital 
warts[1, 8].  The bivalent vaccine produced by GlaxoSmithKline provides protection against 
HPV-16 and 18, and studies show cross-protection against HR-HPV types 31 and 45[9-11]. 
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Penile HPV infection 
The prevalence of HPV in men has been reported to be 10-75% in men, and can vary 
greatly depending on the characteristics of the study population, sample collection method 
(e.g. swab, emery paper for exfoliated cells), anatomical site sampled, and the sensitivity of 
the laboratory HPV assay employed[12-15].  HPV has been associated with 70-100% of 
penile intraepithelial neoplasia and 40-50% of invasive penile cancer[16-18].  Although the 
burden of HPV-associated penile lesions and cancer is relatively low compared to other 
cancers in men such as anal cancer[19], rates of penile cancer have been correlated to rates of 
cervical cancer at the population-level[20].  Men are important carriers of HPV infection and 
may transmit their HPV infection to their female partners susceptible to the development of 
cervical cancer[21, 22].   
 HPV deoxyribonucleic acid (DNA) has been detected in exfoliated cells from the 
penile shaft, glans, coronal sulcus, urethra, scrotum and anus, and in semen and urine[12, 
15].  Relative to cervical HPV infection, our knowledge of penile HPV in men is limited.  
There are an overwhelming number of asymptomatic HPV infections in men with subclinical 
penile lesions, and there are no routine screening programs for HPV infection or HPV-
associated genital lesions in men.  However, studies suggest that the prevalence of male 
penile HPV infection is at least as high as cervical HPV prevalence in women[23-30].  
Detection of penile HPV DNA has been associated with lack of circumcision[26, 28, 31], 
decreased condom use[31, 32], and increased frequency and number of sexual contacts[25, 
27, 28, 31].  
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Multiple HPV infections and type competition 
Coinfection with multiple HPV types has been observed in 20-73% of HPV infected 
males[14, 32-39] and have been associated with an increased risk of HPV acquisition of 
additional HPV types[35, 40-43], HPV persistence[33, 35, 40, 44, 45], and development of 
cervical precancerous lesions in women[46-48].  Multiple HPV infections could have an 
impact on the efficacy of the HPV vaccine due to type competition or type replacement.  
HPV type replacement, a change in the distribution of HPV types found in the population 
when specific HPV types are reduced or eliminated by vaccination, is an important concern 
related to mass HPV vaccination.  Type competition may result from some yet unknown 
biological mechanism, whereby infection with one HPV type inhibits the acquisition or 
persistence of other HPV types[35, 42].  Thus, when one HPV type is prevented by 
vaccination, the prevalence of the other HPV type could potentially increase.  In contrast, if 
infection with one HPV type facilitates the acquisition or persistence of other HPV types, it is 
possible that when one HPV type is prevented by vaccination, the other type might be 
reduced in the population following wide-spread vaccination.   
If HPV types do compete, this will be reflected in the population as a low probability 
of coinfection with two specific HPV types.  However, there are several reasons why, in 
addition to the possibility of type competition, that two HPV types may be unlikely to occur 
together in coinfection.  The prevalence of HPV types detected in a sample population are 
dependent on the HPV type distribution found in the general population in that specific 
geographical area and the HPV types circulating within sexual contacts from whom they 
acquired their HPV infections.  In addition, observed positive associations between HPV 
types may be due to the common transmission route and risk factors for all HPV types, such 
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as age[49-51], condom use[37], circumcision status[34, 52], and lifetime[37, 53, 54] or 
recent[50] number of sexual partners.  Thus, associations between HPV types reflect a 
combination of exposure to HPV, the circulating genotype distribution, individual behavioral 
characteristics, host susceptibility (e.g. acquired immunity or cross-protection), or molecular 
interactions between HPV types that inhibit or facilitate infection with other HPV types[35, 
42, 55].   
 
Molecular studies of multiple HPV infections 
Numerous studies have detected two or more HPV types in cervical and penile 
samples and these studies provide evidence that more than one HPV type can co-exist in the 
same tissue.  However, only a few studies have examined molecular interactions between 
HPV types within individual cells[56, 57].  Simultaneous infection with HPV-40, HPV-11 
and HPV-82 led to regionally separate HPV infections within a single human foreskin 
xenograft in mice[56].  These results suggest HPV types may interact in a way that results in 
the expansion of a dominate type and a concomitant exclusion of other types[56].  An earlier 
study found that several HR-HPV type combinations, electroporated into primary 
keratinocytes, could occupy and replicate within a single cell[57].  This study found evidence 
that HPV types may interact in coinfected cells to produce survival and replication 
advantages for some types, while hindering proliferation of other types.  For example, HPV-
18 maintained higher genomic copies when coinfected with HPV-31 and 39 than when singly 
infected.  It is possible that one viral type can out-compete other types for the necessary 
replication factors, hindering survival and replication of certain types in coinfection[57]. 
 
6 
 
Literature review  
Currently, there is no direct evidence from prospective studies of vaccinated women 
that certain HPV types are either reduced or increased in the population as a result of 
vaccination.  A limited number of studies in women provide information on whether specific 
HPV types are likely to coinfect the genitals[49, 51, 53, 58-63], risk factors for multiple HPV 
infections[50, 53, 63], and whether genital infection with one HPV type modifies the risk of 
acquisition or clearance of another HPV type[40-43, 51].  However, there are no studies of 
multiple HPV infections and type competition in African populations, where the HPV 
genotype distribution may differ from those in North America, Europe or South America, 
and there are no studies in men.   
Previous cross-sectional studies in women have found that the prevalence of multiple 
infections and the number of HPV types detected are observed more often than would be 
predicted by chance alone (Table 1.1)[40-42, 58-60].  Studies have also reported several 
HPV genotypes and phylogenetic clades to be associated with concurrent infection with other 
types and clades.  Among HPV-positive women, one study found HPV-52 and HPV-68 in 
combination with HPV-16, and HPV-18 in combination with HPV6/11 to occur less often 
than expected (p<0.05)[51].  A recent study from Denmark found 31 pair-wise type 
combinations to be positively associated (p<0.05) and found 49 negative associations among 
351 HPV pair combinations (p<0.05)[60].  However, these women were referred for testing 
based on clinical suspicion of infection and only HPV-51 was consistently associated with 
HPV-16[60].  A pooled analysis of women worldwide (n=13,961) found positive 
associations, but no negative associations, between specific HPV pairs: HPV33+35, 
HPV33+58, HPV33+39, HPV18+45, HPV31+35 (p<0.01)[58].  HPV clade-A9 (HPV-16, 31, 
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33, 35, 52, 58) was found less often in multiple HPV infections as compared to all other HPV 
clades (OR: 0.68; 95% CI: 0.48, 0.95) in a population of HIV-infected and uninfected women 
from the United States[59]. 
Numerous prospective studies have found that women with HPV infection at baseline 
are more likely to acquire additional HPV types and that acquisition of multiple HPV types 
occurs more often than expected[40, 42, 43].  In addition, several papers have addressed 
associations between individual HPV types and HPV acquisition(Table 1.2).  In analyses 
limited to five HPV DNA types, current infection with HPV-16, 18, 31, 45 or 6 did not 
predict future acquisition of any other HPV type among female University students[42].  On 
the other hand, in a population of cytologically normal women, there was an increased odds 
of subsequent HPV DNA detection of species A7 genotypes among women with HPV-16 
DNA at baseline compared to women without HPV-16.  In agreement with results from the 
ASCUS/LSIL Triage Study[55], any HPV infection, regardless of type, was associated with 
an increase in HPV acquisition of other types due to a common mode of transmission or 
common risk factors[43].  A pre-existing HPV-16 infection predisposed young women to 
acquiring another HPV type infection but did not affect the persistence of other type 
infections[43].  This finding is consistent with a study of low-income women from Brazil 
that reported an effect of existing infection on the acquisition of another type but not an 
effect on persistence[40].  In contrast, incident infections with HPV-16 and 18 were 
associated with a higher odds of acquiring HPV-58, but not acquiring other types, among 
cytologically normal women from Colombia[41].  
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Conclusions 
When carcinogenic HPV infections are prevented by mass vaccination, there is a 
theoretical possibility that this could result in other HR-HPV types filling the ecological 
niche of HPV-16 and 18[64].  However, there is no direct evidence from prospective studies 
of vaccinated individuals that non-vaccine HPV types are either reduced or increased as a 
result of vaccination against HPV.  Until there are large populations of vaccinated 
individuals, the research community has responded to this potential concern by examining 
the associations between HPV types in observational studies of women.  Since there are 
reported differences in genotype distribution across gender and geographical regions[12, 14, 
65], the potential for HPV type replacement could differ across study populations.  Given the 
recent approval of HPV prophylactic vaccination for young men[66], data on HPV 
coinfections in men are needed to assess associations between HPV types and the potential 
for future HPV type replacement in men. 
 
 
 
 
 
  
 
  
 
II: SPECIFIC AIMS 
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Currently, there are no studies on HPV type competition and associations between 
HPV types throughout the natural history of HPV infections in men.  Therefore, using data 
from a randomized control trial (RCT) of male circumcision in Kisumu, Kenya, we aim:  
 
Specific Aim #1.  To determine the type-specific associations between vaccine 
preventable HPV types and all other HPV types. 
 
 Aim 1.1.  To determine the correlates of multiple HPV type infections. 
 
Aim 1.2.  To determine whether multiple HPV infections occur more often than expected 
under the assumption of independence. 
 
 Aim 1.3.  To determine the association between each of the four vaccine-preventable 
HPV types and all other HPV types. 
 
Hypothesis.  We hypothesize that multiple infections will occur more than expected under 
the assumption of independence.  Further, we will use a hypothesis generating approach to 
identify HPV types that are negatively associated and indicate the potential for HPV 
competition and warrant further investigation. 
 
 
Specific Aim #2.  To determine the associations between prevalent infections with 
vaccine-relevant HPV types and acquisition of other HPV infections over 24 months. 
 
Aim 2.1.  To describe the patterns of HPV acquisition among men with type-specific 
HPV infections at baseline to men without specific HPV types at baseline. 
 
15 
 
Aim 2.2.  To determine if infection with one of six vaccine-relevant HPV type is 
associated with future acquisition of other HPV type infections, for all high-risk HPV 
types in pair-wise combinations. 
 
Hypothesis.  We hypothesize that men with baseline infections with vaccine-relevant HPV 
types will be more likely to acquire additional HPV types over follow-up as compared to 
individuals without baseline infections. 
  
 
III: METHODS 
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Parent study: randomized control trial of male circumcision to reduce HIV  
 A randomized control trial of male circumcision was conducted from 2002-2007 in 
Kisumu, Kenya to assess the effectiveness of male circumcision to reduce the incidence of HIV 
infection (Grant number U01-A150440, P.I. Dr. Robert Bailey)[67].  The study was an unblinded 
randomized trial with two arms: the circumcision arm (intervention arm) and the delayed 
circumcised arm (control arm).  Recruitment began in February, 2002, and enrollment was 
completed in September, 2005.  Local newspapers, radio shows and street performances were 
used to disseminate information about the study.  Potential participants were recruited from STI 
clinics, HIV voluntary testing and counseling centers, workplaces, and community organizations 
that serve unemployed and less-educated young men.  At the first screening visit, potential 
participants were seen by trained counselors to determine if they met the study inclusion criteria, 
below. 
 
Inclusion criteria:         Exclusion criteria: 
Consent to participate         Foreskin covers less than half of the glans 
Uncircumcised         Hemoglobin less than 90 g/L 
HIV seronegative         Hemophiliac or other bleeding disorder 
Sexually active         High prothrombin time index 
Age 18–24 years         Other medical condition contraindicating surgery 
Resident of Kisumu district        Absolute indication for circumcision 
No plans to relocate for at least 2 years  
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Eligible participants were invited for a second screening visit where they provided their 
written informed consent and were enrolled in the trial.  At the next study visit (referred to as the 
baseline or randomization visit), participants were interviewed to obtain information on socio-
demographic status, health, and sexual behavioral.  Study nurses recorded participants’ medical 
history and conducted a medical exam to collect blood and other biological samples.  At this 
visit, men were assigned to either the intervention or the control arm based on randomly 
permuted blocks of size 10 and 20, within age-groups of 18–20 years and 21–24 years, to ensure 
approximately equal age distributions in the intervention and control arms.  Men randomized to 
the circumcision arm were immediately scheduled for surgery; those randomized to the control 
arm were asked to remain uncircumcised until the end of the study, at which time they were 
offered circumcision. 
Study participants were followed at 6 month intervals for a total of 24 months after 
randomization (all visits: 1) baseline/randomization, 2) 6 months, 3) 12 months, 4) 18 months, 5) 
24 months).  At each visit, a behavioral risk assessment, HIV testing and counseling, and STI 
testing and treatment were conducted.  All men were counseled to reduce their risk for HIV and 
other STIs by consistently using condoms and reducing numbers of sex partners.  During the 
medical exam at each visit, the following specimens were collected: blood for rapid HIV, herpes 
simplex virus type 2 (HSV-2) and syphilis (rapid plasma reagin) antibody testing; urine for 
nucleic acid testing for . gonorrhoea and C. trachomatis, and T. vaginalis culture; a genital 
swab from men with urethral discharge for . gonorrhoea and T. vaginalis culture, and . 
gonorrhoea and C. trachomatis polymerase chain reaction (PCR); and a genital sample from 
men with genital ulcers for H. ducreyi culture, and H. ducreyi, syphilis and HSV-2 PCR testing. 
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ested cohort study: natural history of HPV infections in men 
 
Within the RCT is a nested cohort study of the effect of male circumcision on the risk 
and natural history of penile HPV infection among young, sexually active men in Kisumu, 
Kenya (Grant number R01 CA114773-04, P.I. Jennifer S. Smith)[32, 68, 69].  The aims of the 
nested study are to characterize the natural history of HPV infections in uncircumcised males, 
and to assess the effectiveness of male circumcision in reducing penile HPV incidence and HPV 
persistence.  Following the design of the parent RCT, penile samples for HPV DNA detection 
and viral load were collected at baseline for all eligible males, and at biannual study visits 
through 24 months of follow-up for all men enrolled in the RCT and randomized to either the 
intervention or control arm. 
 
Collection of penile samples for HPV DA detection 
 
Men who consented to the nested HPV study had penile exfoliated cells collected from 
two separate anatomical areas at each study visit during the medical examination.  First, using a 
pre-wetted Dacron swab, exfoliated cells were collected by rubbing the external penile shaft 
vigorously a total of eight times with sufficient pressure in order to ensure that an adequate 
number of cells were collected.  For uncircumcised men, this specimen also included a sample 
from the outer, external surface of the foreskin.  Immediately following sample collection, the 
swab from external penile shaft and foreskin (referred to as the shaft specimen), was placed in 
one15mL tube containing Tris buffer.  Next, with a different pre-wetted swab, cells were 
collected by circling the urethral orifice 2-3 times; by sampling back and forth from the top to 
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the bottom of the glans in a circular motion; and by rotating the swab three times completely 
around the circumference of the coronal sulcus.  For uncircumcised men, an additional sample 
was taken using the same swab from the inner foreskin tissue.  Immediately following sample 
collection, the swab of cells from the urethral orifice, glans, coronal sulcus, and inner foreskin 
tissue (referred to as the glans specimen) was placed in a second 15mL tube with Tris buffer.  
Both specimen tubes were sent directly to the Universities of Nairobi, Illinois and Manitoba 
(UNIM) lab to be processed and stored at -80 degrees.   
HPV DA laboratory detection  
Samples were shipped to the Vrije Universiteit Medical Center in Amsterdam, 
Netherlands where they were evaluated for DNA quality by beta (β)-globin specific PCR using 
BGPCO3 and BGPCO5 primers [70].  HPV DNA positivity was assessed on all samples, 
regardless of β-globin positivity, using GP5+/6+ PCR and an enzyme immunoassay (EIA) read-
out system with two HPV oligoprobe cocktails that detect 44 HPV types [70, 71]: 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 (classified as HR-HPV), and 6, 11, 26, 30, 32, 34, 40, 
42, 43, 44, 53, 54 55, 57, 61, 64, 67, 69, 70, 71 (equivalent to CP8061), 72, 73, 81 (equivalent to 
CP8304), 82 (IS39 and MM4 subtypes), 83 (equivalent to MM7), 84 (equivalent to MM8), 85 
(cand85), 86, 89 (cand89 equivalent to CP6108), and JC9710 (classified as LR-HPV).  For the 
full laboratory protocol of PCR methods, see Appendix Document 1.  GP5+/6+ PCR positive 
samples were then subjected to HPV genotyping by reverse line blot hybridization (RLBH) [70].  
HPV types detected by EIA but not by RLBH genotyping were designated as HPV-X, indicating 
a type, subtype, or variant not detectable with RLBH, and were not included in either the HR-
HPV or LR-HPV groups.  For each line blot, PCR products of positive and negative controls 
were included and the procedure was repeated if either one of these controls gave inappropriate 
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results.  In addition to including positive and negative controls in each PCR and detection step, 
reproducibility of the test results was monitored periodically by randomly retesting 5% of 
samples.  This highly specific PCR-EIA detection system with GP5+/6+ consensus primers has 
been shown to have lower rates of cross-hybridization between HPV types[58, 70] but is also 
relatively less likely to detect specific HPV types or multiple infections as compared to other 
detection methods[72, 73].   
Data analysis methods 
Overview  
Our analyses aimed to answer: What is the distribution of HPV genotypes and number of 
concurrent infections among men?  Are men without vaccine preventable HPV types 16, 18, 6, 
11 more or less likely to have a concurrent infection with other specific HPV types?  
Are individuals without vaccine-relevant HPV types 16, 18, 31, 45, 6 or 11 at baseline 
more or less likely to acquire other high-risk HPV types compared to individuals with these HPV 
type infections at baseline? 
 
Sample population 
 Men who were eligible for inclusion in the RCT (4,489 of 5,622 screened), and who 
consented to the HPV nested study and provided a penile sample at baseline (2,702 of 4,489) 
made up the sample population for analysis of study aim #1 (Figure 3.1).  Men in this sample 
were HIV-negative, uncircumcised and were age 17-28 years.  The study population for specific 
aim #2 were men who consented to the HPV nested study (2,702 of 4,489), who were enrolled in 
the RCT (2,228 of 2,702), who were randomized to the control arm (1,102 of 2,228) and who 
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had HPV DNA samples at baseline and at least one follow-up visit (1,064 of 1,102).  Men in this 
sample were age 18-24 years and fully met all RCT inclusion criteria. 
Categorization of HPV DA results for analysis 
 
For both specific aims #1 and #2, one of 44 HPV types was considered the exposure type 
and one of the other 43 HPV types was considered the outcome type, in order to determine the 
pair-wise associations between HPV types.  All analyses were based on pooled HPV status rather 
than separate glans and shaft site-specific HPV status.  This is because the aims relate to HPV 
vaccination that provides overall not site-specific protection against HPV infection.  
Furthermore, it is likely that an HPV type detected in the glans is also present on the shaft but it 
is less likely to be detected because of fewer exfoliated cells per sample[15].  In addition, main 
analyses included HPV DNA results regardless of detectable β-globin.  As summarized in the 
results of previous publications from this cohort[32] and in the results section below (Chapter 6), 
approximately 70% of samples tested β-globin positive.  The prevalence of HPV did not differ 
between β-globin positive and negative samples.  HPV infections, rather than men, were treated 
as the unit of analysis because men could be simultaneously infected with multiple HPV types at 
any given time.  Infections that could not be genotyped by RLBH were not included in either the 
HR-HPV or LR-HPV groups. 
 Figure 3.1.  Study design and sample population for dissertation aims
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Analysis of specific aim #1 
Exposure and outcome definitions 
Specific aim #1 focused on cross-sectional associations between the four vaccine-
preventable HPV types (defined as 16, 18, 6, and 11) and all other 41 HPV types in pair-wise 
combinations: HR-HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and LR-HPV 26, 30, 
32, 34, 40, 42, 43, 44, 53, 54 55, 57, 61, 64, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, 85, 86, 89, 
JC9710, and HPV-X.  In addition, the distribution and correlates of multiple versus single 
HPV infections were described.  A single infection is defined as baseline HPV DNA 
positivity to any one single HPV type in the glans and/or the shaft.  For example, if HPV-16 
was detected in the glans but not the shaft, or if HPV-16 was detected in both the glans and 
the shaft, an infection was classified as a single type infection.  A multiple infection is 
defined as the detection of two or more different HPV types in either the glans or the shaft 
combined, regardless of the HPV types.  For example, if HPV-16 was detected in the shaft 
and HPV-35 in the glans, or if HPV-16 and HPV-35 were detected in the glans and no HPV 
was detected in the shaft, an infection was classified as multiple type infection. 
 
Missing data 
All men included in the cross-sectional analysis of aim #1 provided a baseline HPV 
DNA sample (N=2,702).  However, covariate data were missing (see Table 3.1 below for a 
detailed list of missing data).  We did not impute missing values for covariates in the analysis 
of correlates of multiple infections but rather proceeded with a complete-case analysis since 
less than 5% of participants had incomplete data.  Because potential confounding variables 
were only included in the first stage Bayesian models to calculate the adjusted prior 
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probabilities, missing data did not limit men from entering the hierarchical logistic regression 
analyses of HPV type associations (N=2,702). 
 
The observed vs. expected number of HPV types 
The distribution of the number and types of HPV detected were described (see 
Appendix Table 1 for the distribution of HPV types detected in single vs. multiple HPV 
infections, and Appendix Figure 1 for a graphical representation of HR vs. LR types in 
multiple and single infections, and of the number of HPV types stratified by type-specific 
HPV infection at baseline).  The observed number of men with 0, 1, 2, 3, 4, 5, and 6 or more 
concurrent HPV types detected was compared to the frequency that would be expected under 
the assumption that each HPV infection is independent of all others.  For each man, infection 
with each of the 45 possible HPV types was simulated by random generation of a binary 
variable with the probability of infection equal to the observed prevalence of that type in the 
study population[42].  The expected frequencies of each number of HPV infections were then 
calculated as the average frequency over the 1,000 stochastic simulations of 2,702 
observations.  The observed prevalence of the 14 HR-HPV types was used to simulate the 
expected number of infections with only high-risk HPV types.  Data simulation, as opposed 
to multiplication of the marginal probabilities, was a much more efficient method to 
determine the expected number of infections.  For example, in order to determine the 
expected frequency of infection with any two HPV types without data simulation, 990 
probabilities would have to be calculated (e.g. 45 chose 2 to determine the probability of 
being positive for type 1-2 and negative for all other types, plus the probability of being 
positive for types 3-4 and negative for all other types, etc).   
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Two-sided p-values were calculated to determine if the observed frequency of 0. 1, 2, 
3, 4,5, 6+ infections was less than or greater than the expected frequency if each infection 
was independent.  For i=0 to 6+ HPV types, Oi was the observed number of men with i 
infections, and Ei was the expected number of men with i infections based on data 
simulations.  For simulated the datasets j=1 to 1000, Oij was the number of men with i 
infections in the j
th
 dataset.  Thus, the two-sided p-value was calculated as proportion of 
simulated data sets where |Oij-Ei| >= |Oi-Ei|. 
 
Correlates of multiple HPV infections 
Study covariates that were investigated as potential correlates of multiple HPV 
infections were identified in the previous literature on multiple infections in men and women 
and previous baseline analysis of this cohort[32, 37, 74].  The categorizations of the variables 
that we considered in our analysis are outlined below (Table 3.1).   
Univariate logistic regression was used to estimate odds ratios (ORs) and 95% 
confidence intervals (CIs) for potential correlates of multiple versus single HPV infections.  
Multivariate logistic regression was used to estimate associations between each potential 
correlate and multiple HPV infections, simultaneously adjusting for all other potential 
correlates.  These variables were also considered potential confounders in the analysis of 
HPV type associations, below. 
The degree of collinearity between variables included in the multivariate model was 
assessed by examining the variance inflation factor (VIF) and tolerance (1/VIF) values.  No 
VIF values exceeded the cut-off of 10 (equal to a tolerance value less than 0.1), which was a 
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value chosen to highlight variables likely to be a linear combination of other variables in the 
model[75].  
 
Table 3.1.  Covariates considered in univariate and multivariate models as potential 
correlates of multiple HPV infections 
Study covariates Missing Model inclusion Justification 
Age (in years) n=0 Continuous Previous literature on prevalence 
and acquisition of HPV infections 
Travel to Nairobi (6 months 
prior to baseline) 
n=5 Binary (any/none) Potential exposure to additional 
HPV types and relates to SES 
Bathing frequency n=14 Binary           
(daily/less than) 
Baseline paper on risk factors, to 
represent male hygiene
a
 
Number of partners (6 
months prior to baseline) 
n=23 Categorical                
(0-1 vs. 2+) 
Previous literature and baseline 
paper on risk factors 
Condom use  (6 months 
prior to baseline) 
n=129 Binary
b
              
(always, not always) 
Previous literature and baseline 
paper on risk factors 
. gonorrhea n=23 Binary  (detected/not) Baseline paper on risk factors and 
represents marker of sexual 
activity/sexual risk behaviors 
C. trachomatis n=24 Binary  (detected/not) Baseline paper on risk factors and 
represents marker of sexual 
activity/sexual risk behaviors 
a
Baseline paper on risk factors for HPV infection within this cohort (J. Smith, IJC, 2010) 
b 
“Always” category includes men who report no sex in last 6 months 
 
 
Semi-Bayesian methods for HPV type associations 
Next, hierarchical regression analysis was used to obtain semi-Bayes estimates of the 
ORs[76] between the four vaccine-preventable HPV types and 41 other outcome HPV types, 
adjusting for potential confounders of the association between HPV types.  When data are 
sparse, shrinkage methods, such as the one we used here, reduce the overall error in the set of 
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estimates as compared to maximum likelihood estimation (MLE).  Prior information from the 
study data (in this analysis: the average association between all types) and from the literature 
(in this analysis: the range of expected odds ratios) are incorporated into these two-stage 
models[77-79]. 
The type-specific prior means for HPV-16, 18, 6 and 11, µj, where j = 1 to 4, were 
estimated from the data and their variability was propagated through hyperpriors.  The µj are 
the average of the log odds ratio between the individual vaccine type and all 41 other HPV 
types, adjusted for age, travel to Nairobi (in 6 months), bathing frequency, number of sexual 
partner (in 6 months), consistent condom use (in 6 months), and current Gonorrhea and C. 
trachomatis infection.  Multivariate logistic regression models for all 164 pair-wise 
combinations (4 exposure types by 41 outcome types) were conducted to obtain the 
individual adjusted ORs.  Then, the crude averages of the ORs were calculated separately for 
each of four exposure types.  Thus, the prior inputs for the semi-Bayesian model were: 
µ16=0.6796, µ18=0.9264, µ6=0.6238, µ11=0.7605.  A hyperprior for the type-specific prior 
means was added to the models to express our uncertainty around the estimates of µj [78].  
The hyperprior, µH, was normally distributed with a mean zero and a variance of 0.5.  Next, 
we assumed that 95% of the log odds ratios should fall within a 5-fold range based on 
previous literature [41-43, 55, 60].  Thus, the prior variance for each µj, τ
2
, was set equal to 
0.169 in the main analysis, which was back calculated from the assumed OR range: τ
2 
= 
{[ln(ORU)-ln(ORL)]/3.92}
2
.  Model estimates are reported as the exponentiated posterior 
medians and 95% credible intervals, analogous to ORs and 95% CIs.  
Semi-Bayesian logistic regression was implemented in SAS version 9.2 using the 
PROC MCMC (Markov Chain Monte Carlo) procedure.  An example of the SAS code is 
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provided, which highlights model settings and parameterization (Appendix document 2).  
The models were set with 2,000 burn-in iterations, 2,000 tuning iterations and 80,000 
MCMC iterations (excludes burn-in) with a thinning rate of 10 (only 1 out of every 10 
iterations is kept).  The final models settings were chosen based on a review of model fit and 
in accordance with current expectations in the literature (personal communication with Dr. 
Steve Cole: a review of PROC MCMC SAS coding, model diagnostics, and iteration 
settings).  Representative sets of diagnostic plots (HPV-45 and HPV-52) for model 
convergence and fit are presented in Appendix Figure 2:   
1. The stable mean of the trace plots indicates the Markov chain has converged and 
the full coverage (e.g. traces span the full range and are thick) of the plots 
indicates the models have good mixing. 
2. The plots of autocorrelations of the posterior samples shows that the 
autocorrelations drop quickly and remain zero after 5-10 lags, which shows the 
model settings were sufficient.  
3. The kernel density plots show the distribution for the estimates of the posterior 
marginal distributions for each parameter, which are a smooth, bell-shape, 
indicating a well-fit model. 
 
Sensitivity analyses 
1)  The case of the bivalent HPV vaccine was also considered; analyses were 
conducted as outlined above except only two vaccine types, HPV-16 and 18, were considered 
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the exposure types, and the 43 other types, including HPV-6 and 11, were considered the 
outcome types (results presented in Chapter 4). 
2)  The precision of the estimates from the semi-Bayesian logistic regression is 
partially dependent on the value of the prior variance of the prior probabilities, τ
2
.  
 
We 
explored the results obtained when setting τ
2
 to 0.35, which reflects a 10-fold difference in 
the prior 95% confidence limits and 1.38, which reflects a 100-fold difference in the prior 
95% confidence limits (results presented in Chapter 4). 
3)  Previous studies of HPV type associations and competition have used maximum 
likelihood estimation techniques.  Therefore, to compare our results with other published 
studies, ORs of HPV type associations were also estimated using maximum likelihood 
logistic regression.  These models were constructed in the same manner as the semi-Bayes 
models: the individual models for each of the 41 outcomes types contained the four exposure 
HPV types and the covariates age, travel to Nairobi, bathing frequency, number of sexual 
partner, consistent condom use, and current Gonorrhea and C. trachomatis infection (results 
presented in Chapter 4). 
 
Strengths and limitations 
 Although the analytical methods for specific aim #1 improved upon previous studies, 
there are several limitations to highlight in order to properly interpret the results.  First, there 
were no data on immunological susceptibility and no data on HPV types detected in female 
sexual partners.  These unmeasured cofounders could affect HPV infection status and 
genotype distribution, and thus affect the observed associations between HPV types.  
Although we were able to adjust for several measured behavioral factors that are potential 
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confounding variables, the observed associations between HPV types are influenced by 
unmeasured factors that cause positive (e.g. shared risk factors and transmission routes) and 
negative (e.g. low prevalence of specific HPV types or potential type competition) 
associations between HPV types.   
Using multiple models to draw conclusions regarding 164 pair-wise HPV type 
associations raises the problem of multiple comparisons, which can increase the probability 
of falsely concluding HPV types associated.  On the other hand, the number of comparisons 
in our analysis is reduced compared to previous studies[58-61].  By including all four 
exposure types in each model, we not only adjusted for infection with the other HPV types 
but fewer models were needed to determine all pair-wise associations.  The semi-Bayesian 
methods have increased power to detect differences between even rarer HPV types and 
reliably reduce the overall error in the set of estimates because of the information gained by 
incorporating prior probabilities into two stage modeling[77-79].  However, it is important to 
note that when the data are sparse, the prior information carries more weight in the regression 
analysis and the estimates are shrunk towards the grand mean, while estimates with more 
data will be less influenced by the prior probabilities.   
 
Analysis of specific aim #2 
Exposure and outcome definitions 
Specific aim #2 was a prospective analysis that focused on the association between 
type-specific HPV infection at baseline and acquisition of additional HPV infections over 24 
months of follow-up.  The exposure of interest was a baseline infection with HPV-16, 18, 31, 
45, 6, or 11.  HPV types 16, 18, 6 and 11 were chosen as baseline types of interest due to 
32 
 
their inclusion in current generation HPV prophylactic vaccines.  Given the relatively high 
prevalence of HPV 45 in adenocarcinoma and the potential for HPV cross-protection against 
HPV-31[10], we also investigated associations between HPV-31 and 45 and future HPV 
acquisition.  The outcome was acquisition of any-HPV, HR-HPV and each 1 of 14 HR-HPV 
types over 24 months of follow-up (Table 3.2).  In both the analysis of group and individual 
HPV type outcomes, type-specific HPV acquisition was defined as the detection of a new 
genotype at the current visit that was not detected at any of the previous study visits.   
 
 
Table 3.2.  Index and referent groups for the analysis of HPV acquisition 
Baseline exposures of interest Acquisition outcomes of interest
a
 
Vaccine-relevant types  
HPV16+  vs.                                                             
HPV16- 
Any-HPR, HR-HPV, HPV-18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, 68 
HPV18+  vs.                                                      
HPV18- 
Any-HPR, HR-HPV, HPV-16, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, 68 
HPV31+  vs.                                                        
HPV31- 
Any-HPR, HR-HPV, HPV-16, 18, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, 68 
HPV45+  vs.                                                       
HPV45 
Any-HPR, HR-HPV, HPV-16, 18, 31, 33, 35, 39, 51, 52, 
56, 58, 59, 66, 68 
HPV6+  vs.                                                           
HPV6- 
Any-HPR, HR-HPV, HPV-16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, 68 
HPV11+  vs.                                                        
HPV11- 
Any-HPR, HR-HPV, HPV-16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, 68 
Vaccine-relevant groups  
HPV16 and/or 18+  vs.                                        
HPV16 and 18- HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 
HPV6 and/or 11+  vs.                                          
HPV6 and 11- HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 
HPV16, 18, 6 and/or 11+  vs.                
HPV16, 18, 6, 11- HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 
a
Outcome group or type always excludes the exposure HPV type of interest in each analysis 
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Time to event: interval censoring methods 
 Interval censored survival methods for time to first acquisition for each HPV type 
were used because the actual time of acquisition was not directly observed; acquisition 
events are only known to have occurred between the last HPV negative visit and the first 
HPV positive visit[80].  For each HPV type where an event was not observed, the data were 
right-censored at the final study visit (Figure 3.2).  If men crossed-over to the circumcision 
arm during follow-up before experiencing an event, they were right-censored at their last 
visit with HPV DNA results prior to their circumcision.   
 The intervals were used to accommodate missing visits where HPV DNA results 
were unavailable.  If the visit(s) before the first HPV positive visit was missing, the interval 
was widened to accommodate the missing observation(s).  For example, the left interval was 
the last HPV negative visit date and the right interval was the first HPV positive date, with 
the missing visit inside this interval.  If HPV DNA results were missing in between two HPV 
negative visits, then the missing value was assumed to be HPV negative and it was not 
included inside the acquisition event interval.   
 
 
 
 
 
 
 
 
 
 Figure 3.2.  Diagram of interval censoring scheme used in time
 
 
Parametric survival models 
 Parametric frailty survival models were used to estimate the overall association 
between type-specific infections at baseline and acquisition of any
Parametric frailty models account for the correlation between HPV types among men who 
acquire multiple infections[81]
assumed to follow a Weibull distribution, such that the model can be viewed as either an 
accelerated failure time model or a proportional hazards model
model, 

for the i
th
 participant and the 
random frailty effect, which
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-to-event analyses
-HPV and HR
 and allow for interval censored data.  Survival times were 
[81, 82].  In the Weibull 
	
  


    	,  
j
th
 HPV genotype, where 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exp(β) represents the adjusted hazard ratio (aHR) and exp(

 β)represents the adjusted 
median survival ratio (aMSR) for men with a baseline HPV type compared to men without 
that baseline type.  aHRs less than 1.0 indicates a lower rate of HPV acquisition among men 
positive for a specific HPV type compared to men negative for that same type at baseline, 
adjusted for potential confounding variables.  Similarly, the aMSRs compare the median 
survival time among HPV infected versus uninfected men at baseline, adjusted for potential 
confounding variables.   
Parametric survival models without the random effects frailty term were used to 
estimate the aHRs for the associations between prevalent HPV types and acquisition of each 
one of the 14 individual HR-HPV types. In the Weibull model: 
 
 
  

  
,
 is the shape parameter,  is a vector of covariate values and  is a  
vector of coefficients 
 
 Variables were identified as potential confounders of the association between 
baseline HPV type and time to acquisition of additional HPV types through an extensive 
review of the literature.  A directed acyclic graph (DAG) was used determine the minimally 
sufficient set of adjustment variable to best control for confounding (Figure 3.4).  All models 
of HPV acquisition were adjusted for potential confounding variables, including baseline 
measurement of age (continuous centered at the median age of 20 years; no missing), male 
hygiene (daily vs. less than daily bathing frequency; missing=13), number of sexual partners 
in 6 months prior to baseline (0-1 vs. ≥2; missing=4), consistent condom use in 6 months 
 prior to baseline (self-reported always vs. less than always
the presence of C. trachomatis
HPV infections; missing=12).  
population so a complete case analysis approach was used.
 
Figure 3.4.  Directed acyclic graph
time to acquisition of other HPV types
 
 
 
Survival curves to assess model fit and describe patterns of HPV acquisition
 Survival curves were used to graphically display the pattern of HPV acquisition by 
HPV-16, 18, 31, 45, 6 and 11 DNA status at baseline.  The survival function, which describes 
the probability that an HPV infection has not been acquired as a function of tim
estimated using the nonparametric maximum likelihood estimator (NPMLE)
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 condom use; missing=115
 (baseline STI shown in aim #1 to be associated with multiple 
Covariate data was complete for ~90% of the sample 
 
 of the associations between baseline HPV types and 
 
 
[83, 84]
) and 
 
e, was 
, which 
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is the general form of the Kaplan-Meier estimator for interval censored data.  We used the 
published SAS macro %ICE, which is appropriate for data that are arbitrarily censored at 
varying times and with varying interval widths[80].  This macro produces survival function 
estimates and confidence limits for one or more groups using the iterative convex estimator 
(ICE) of Wellner and Zhan[85].  This method has been shown to be an efficient method for 
computing the NPMLE of the survival function with interval-censored data.  We chose to 
graph the cumulative distribution function, which is one minus the survival function (F=1-S), 
so the figures represent the cumulative probability of HPV acquisition.   
 To assess model fit, the NPMLE of the survival function for each baseline HPV type 
were plotted along with the parametric estimates of the survival function estimated by the 
Weibull frailty model (Appendix Figure 3).  The survival functions were not adjusted for 
other covariates, however, the frailty models do account for multiple HPV acquisitions.  A 
good model fit is indicated by overlapping survival curves, with similar shape and values, 
from both the nonparametric and parametric models.  The absolute values of the probability 
of HPV acquisition are consistently slightly lower for the parametric MLE than the 
nonparametric estimates.  However, both sets of curves are monotonic and have a similar 
shape, showing an increase in HPV acquisition over time.  Curves from both the parametric 
models with an assumed Weibull distribution for the survival time and the nonparametric 
models indicate the same general conclusions regarding the relative probabilities of 
acquisition among men with as compared to without baseline infections with each of the six 
HPV types (HPV-16, 18, 31, 45, 6, or 11).   
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Sensitivity analyses 
1)  The main analysis of any-HPV and HR-HPV acquisition was conducted using 
parametric survival models with a random effects frailty term and adjustment for several 
confounding variables.  Therefore, models without the frailty term and adjustment variables 
were also conducted for any-HPV and HR-HPV acquisition (Appendix Table 2).  In general, 
there was little difference between adjusted and unadjusted aHRs for HPV acquisition.  The 
precision of estimates from the models that included the frailty term, which took into account 
the possible correlation between HPV among men with multiple infections, was reduced 
compared to the equivalent model without the frailty term. This implies that each additional 
infection contributed less information to the model than if all infections were considered 
independent, as in the non-frailty models. 
2)  Men with no HPV for prolonged periods of time may differ from men who have 
HPV over a two year period, either behaviorally or immunologically.  Therefore, we 
conducted additional frailty modeling analyses restricted to just men who had at least on 
HPV type detected at least once (results presented in Chapter 5).   
3)  In construction of the censoring intervals, we assumed that a missing HPV DNA 
result that was between two HPV negative visits, was also HPV negative (limited case of last 
value carried forward).  An alternative choice would be to use imputation methods to assign a 
value to the missing HPV data.  Data imputation would assign some missing values to be 
HPV negative and some to be HPV positive based on the pattern of covariate data.  The 
overall effect on our estimate of HPV acquisition would be somewhere in between assuming 
all missings were HPV negative or positive.  Therefore, to better understand our HPV-
negative assumption, and to gage the utility of imputation methods, we changed the missing 
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value to HPV positive and re-analyzed the data.  The point estimates and confidence intervals 
from the sensitivity analysis were very similar to the results of the original analysis 
(Appendix Table 3).  Therefore, we proceeded with our original method and did not use data 
imputation methods. 
 
Strengths and limitations  
 This analysis was limited to men randomized to the control arm.  Therefore, the 
sample size is smaller than full cohort and it’s possible that the results are not generalizable 
to circumcised men.  The smaller samples size could result in reduced power to detect 
differences by baseline status, especially for rarely acquired HPV types.  In addition, the 
analysis of aim #2 also has the problem of multiple comparisons since only one outcome type 
or group is included in each model.  However, it was important to examine all high-risk pair-
wise associations between vaccine-relevant HPV types and future HR-HPV acquisition, as 
these relate to risk of anogenital cancers and the impact of HPV vaccination.  This analysis 
focused only on HPV acquisition but HPV persistence may also differ by HPV type.  The 
association between type-specific HPV infections and HPV persistence will be examined in a 
future analysis.  Splitting HPV acquisition and HPV persistence into separate papers allows 
us to explore both topics in-depth with numerous HPV group and type-specific analyses. 
We used novel survival methods to account for correlation between types among men 
who acquire multiple HPV infections in the analysis of grouped outcomes (e.g. any-HPV and 
HR-HPV).  Another strength of our analysis is the method of calculating time-to-event.  We 
chose to use interval censoring techniques because it requires fewer assumptions regarding 
when the event happened, as opposed to test date or mid-point assumptions.  Interval 
censoring methods are appropriate for time-to-event determination for epidemiologic data, 
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particularly for studies with biannual testing intervals for an infection as dynamic HPV.  In 
addition, by using interval-censoring, the only assumption we had to make regarding missing 
data was that  a missing value in between two negative tests was HPV negative since all 
other missed visits were included in the acquisition interval.  This method required fewer and 
potentially more realistic assumptions than carrying the last value forward for all missing 
data.  Also, if we had instead chosen to censor individuals at the first missed visit, we would 
have reduced our sample size and power; a lot of men who were missing at 6 months 
returned for study visits at 12, 18, and 24 months. 
  
 
IV: MULTIPLE HUMA PAPILLOMAVIRUS IFECTIOS  
AD TYPE COMPETITIO AMOG KEYA ME 
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Abstract 
Background: There is little information on multiple HPV infections and the potential for type 
competition in men, yet competition may impact the type-specific efficacy of HPV 
vaccination.   
 
Methods: To assess the potential for HPV type competition, adjusted odds ratios for pair-
wise combinations of prevalent HPV type infections were estimated using semi-Bayesian 
methods among 2,702 uncircumcised, HIV-seronegative men in Kisumu, Kenya.  The 
observed numbers of HPV types detected were compared to the expected number, which was 
simulated under the assumption of independent infections.   
 
Results: Half of all men were HPV positive, of whom 57% had multiple HPV types.  We 
observed men without HPV infection and with four or more HPV types more often than 
expected if infections were independent.  No negative associations between individual HPV 
types were observed.  HPV types 31, 39, 56, 58, and 59 were positively associated with both 
carcinogenic vaccine types HPV-16 and 18 (two-sided p-value <0.05).   
 
Conclusions: Men who were HPV infected were likely to test positive for more than one 
HPV type.  Cross-sectional associations between individual HPV types were positive and did 
not appear to be type-specific.  Thus, we did not identify HPV types that are candidates for 
potential HPV type competition in men.   
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Introduction 
Human papillomavirus (HPV) infection is the main cause of cervical cancer in 
women[3, 86], and responsible for other genital cancers, including anal and penile carcinoma 
in men.  Co-infection with multiple HPV types is common and observed in 20-73% of HPV 
infected males[14, 32-38, 52].  Multiple HPV type infections have been associated with 
acquisition of other HPV types and increased HPV persistence in men[35], and cervical 
precancerous lesions in women[46-48]. 
There are currently two FDA-approved HPV vaccines that provide protection against 
HPV-16 and 18 [9-11] or HPV-16, 18, 6 and 11 [5-7].  Nearly 70% of cases of cervical 
cancer have been attributed to infection with oncogenic HPV types 16 and 18[1, 8] and low-
risk HPV types 6 and 11 are responsible for the 90% of genital warts.  HPV type co-
infections could affect the population-based impact of HPV vaccination in both young 
women and men due to potential HPV type competition and subsequent type replacement[40, 
41]; that is, an increase in the prevalence of non-vaccine HPV types in the population when 
vaccine-preventable HPV types are reduced or eliminated[51].  Type competition may result 
from some yet unknown biological mechanism, whereby infection with one HPV type 
inhibits the acquisition or persistence of other HPV types [35, 42].  In contrast, if infection 
with a specific HPV type facilitates the acquisition or persistence of other HPV types, it is 
possible that when one HPV type is prevented by vaccination, the other type might be 
reduced in the population.   
If HPV types do compete, this will be reflected in the population as a low probability 
of co-infection with two specific HPV types.  However, there are several reasons why, in 
addition to the possibility of type competition, that two HPV types may be less likely to 
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occur together within a multiple infection.  The prevalence of HPV types detected in a 
sample population are dependent on the HPV type distribution in the general population in 
that geographical area, as well as the HPV types circulating within their networks of sexual 
contacts.  In addition, observed positive associations between HPV types may be due to the 
common transmission route and risk factors for all HPV types, such as age[49-51], condom 
use[37], circumcision status[34, 52], and lifetime[37, 53, 54] or recent[50] number of sexual 
partners.  Thus, any association between individual HPV types reflects a combination of 
exposure to HPV, the type distribution among sexual contacts, and immunological and 
behavioral characteristics[35, 42, 55].   
To date, there are no detailed studies of multiple HPV infections and type competition 
in an African population, where the HPV genotype distribution may differ from those in 
North America, Europe or South America[65].  Given the recent approval of HPV 
prophylactic vaccination in the United States for young men[66], data on HPV co-infections 
in men and their female sexual partners are needed to assess the potential for future HPV 
type replacement.  Using data from a randomized control trial of male circumcision in 
Kisumu, Kenya[67, 69], we investigated the association between vaccine-preventable HPV 
types (16, 18, 6 and 11) and 41 other HPV types using semi-Bayesian methodology. 
 
Methods 
Study population and design 
From February 2002 to December 2006, a randomized controlled trial (RCT) was 
conducted in Kisumu, Kenya to determine the effectiveness of male circumcision in reducing 
HIV incidence[67].  Male participants were recruited from sexually transmitted infection 
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(STI) clinics, workplaces, and community organizations.  To be included in the RCT, males 
were required to be between 18-24 years old, uncircumcised, HIV seronegative, sexually 
active, and have a hemoglobin level of 90 g/L or more.   
An observational cohort study of the effect of circumcision on the natural history of 
HPV infection was nested in the RCT[32, 68, 69].  The present analysis is a cross-sectional 
study at the baseline visit of uncircumcised, HIV-seronegative men who were eligible for 
participation in the main RCT (n=4,489) and who consented to HPV testing (2,705)[32].  In 
the present analysis, three men were excluded due inconsistent records in the database.  The 
final population for this analysis includes 2,702 men who provided penile samples and 
information on sexual risk factors at baseline, of which 2,228 were enrolled in the RCT.  The 
study protocol was approved by the Institutional Review Boards at all collaborating 
Institutions. 
 
Medical examination and sample collection 
 After participants provided informed consent, trained male interviewers administered 
a standardized questionnaire on sociodemographic characteristics, medical conditions, and 
sexual behavior.  A trained physician or clinical officer conducted a physical exam during 
which a genital examination was conducted to visually inspect for ulcers and warts.  Blood 
was collected for HSV-2 (Kalon Biological, Ltd) and syphilis testing (Becton Dickinson; 
RPR with TPHA confirmation).  Urine samples were collected for PCR detection of . 
gonorrhea and Chlamydia trachomatis (Roche Diagnostics).  
Exfoliated penile cells were collected from two anatomical sites using two pre-wetted 
Dacron swabs: i) the shaft and external foreskin tissue (the shaft specimen) and ii) the glans, 
46 
 
coronal sulcus and inner foreskin tissue (the glans specimen)[69].  The penile swabs were 
placed in separate 15-mL centrifuge tubes containing 2-mL Tris buffer 0.01M and processed 
on the day of collection.  All samples were sent to the Department of Pathology at the VU 
University Medical Center for laboratory detection of HPV DNA.   
  
Detection of HPV DA 
Laboratory detection.  HPV DNA testing was performed on uncircumcised men at 
the baseline study visit.  DNA was isolated from exfoliated penile cell samples[70, 71] and 
the presence of human DNA was evaluated by beta-globin-specific polymerase chain 
reaction (PCR), followed by agarose gel electrophoresis.  The presence of HPV DNA was 
assessed by GP5+/6+ PCR, followed by hybridization of PCR products using an enzyme 
immunoassay readout with 2 HPV oligoprobe cocktail probes that together detect 44 HPV 
types.  Subsequent HPV genotyping was performed by reverse line blot (RLBH) 
hybridization of PCR products, as described elsewhere[70, 71].  HPV types 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were classified as high-risk (carcinogenic) HPV 
types.  Low-risk types included 6, 11, 26, 30, 32, 34, 40, 42, 43, 44, 53, 54 55, 57, 61, 64, 67, 
69, 70, 71 (equivalent to CP8061), 72, 73, 81 (equivalent to CP8304), 82 (IS39 and MM4 
subtypes), 83 (equivalent to MM7), 84 (equivalent to MM8), 85 (cand85), 86, 89 (cand89 
equivalent to CP6108), and JC9710.  Types considered vaccine-preventable are HPV-16, 18, 
6 and 11, whereas all others are non-vaccine preventable HPV types.  HPV types detected by 
enzyme immunoassay but not genotyped were designated as HPV-X, indicating a type, 
subtype, or variant not detectable with RLBH probes. 
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Definition of multiple infections.  HPV DNA detection methods were carried out on 
the shaft and glans samples separately.  Given that the aims of the present analyses relate to 
evaluating the potential for HPV type replacement following population-based HPV 
vaccination and not site-specific infection, we present pooled HPV results for the shaft and 
glans specimens.  A single infection is defined as HPV DNA positivity to any one single 
HPV type in the glans, the shaft, or both sites.  A multiple infection is defined as the 
detection of two or more different HPV types in either the glans or the shaft combined.  For 
example, if a man was HPV-16 positive in the shaft and HPV-35 positive in the glans, or if a 
man was HPV-16 and HPV-35 positive in the glans and HPV negative in the shaft, in either 
case the man was classified as having multiple infections.  
 
Statistical analysis 
Distribution of number of HPV genotypes.  The observed number of men with 0, 1, 2, 
3, 4, 5, and 6 or more concurrent HPV type infections was compared to the frequency that 
would be expected under the assumption that each HPV infection is independent of all 
others.  Infection with each of the 45 possible HPV types was simulated for each man by 
random generation of a binary variable with the probability of infection equal to the observed 
prevalence of that type in the study population.  Expected frequencies for each number of 
concurrent HPV infections were calculated as the average frequency over 1,000 stochastic 
simulations of 2,702 observations[42].  For HR-HPV simulations, the observed probabilities 
of the 14 HR-HPV types were used to simulate the expected number of infections with only 
high-risk HPV types.  As done previously[32], all analyses included males who were HPV 
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positive regardless of beta-globin positivity and were conducted using SAS version 9.2 
(Cary, NC). 
Correlates of multiple HPV infections.  Univariate logistic regression was used to 
estimate odds ratios (ORs) and 95% confidence intervals (CIs) for potential correlates of 
multiple versus single HPV infections.  Variables were identified a priori as potential 
correlates of multiple HPV infection based on the previous literature[32, 35, 37].  
Multivariate logistic regression was used to estimate associations between each potential 
correlate and multiple HPV infections, simultaneously adjusting for all other potential 
correlates.    
HPV type associations.  We used hierarchical regression analysis to obtain semi-
Bayes estimates of the ORs [76] between the four vaccine-preventable HPV types and 41 
other outcome HPV types, adjusting for the potential correlates of multiple HPV infections.  
Shrinkage methods, such as the one we used here, reliably reduce the overall error in the 
ensemble of estimates, by incorporating prior information from the study data and the 
literature[77-79].  HPV-16, 18, 6 and 11 type-specific prior means, µj, where j =1 to 4, were 
estimated from the data and their variability was propagated through hyperpriors.  The µj are 
the average of the log odds ratio between the individual vaccine type and all 41 other HPV 
types, adjusted for age, travel to Nairobi (in 6 months prior to baseline), bathing frequency, 
number of sexual partners (in 6 months prior to baseline), consistent condom use (in 6 
months prior to baseline), and current Gonorrhea and C. trachomatis infections.  The prior 
variance for each µj, τ
2
, was set equal to 0.17 because we assumed that 95% of the log odds 
ratios should fall within a 5-fold range based on previous literature [41-43, 55, 60], which 
corresponds to a variance of [ln(5)/3.92]
2
 = 0.17. 
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Model estimates are reported as the exponentiated posterior medians and 95% 
credible intervals, analogous to ORs and corresponding 95% CIs.  Potential evidence of HPV 
type non-independence is an OR estimate less than 1.0: the odds of a non-vaccine 
preventable type are lower in men with a vaccine-preventable HPV type compared to men 
without a vaccine-preventable type.   
Sensitivity analysis.  The case of the bivalent HPV vaccine was also considered; 
analyses were conducted as outlined above, except HPV-16 and 18 were considered exposure 
types, and the 43 other types, including HPV-6 and 11, were considered outcome types.  
Further, we explored results obtained when setting tau
2
 to 0.35 or 1.38, reflecting a 10- and 
100-fold prior 95% confidence limit.  For comparison, maximum likelihood estimates of 
HPV type associations are also presented (online Appendix Table 1). 
 
Results 
Among 2,702 men, with a median age of 20 years (range: 17-28), 51% of men were 
HPV positive (n=1,379).  A single HPV type was detected in 22% (n=592) and multiple HPV 
types were detected in 29% (n=787) of men.  The five most prevalent types overall were 
HPV-16 (n=263; 10%), HPV-X (n=164; 6%), HPV-56 (n=164; 6%), HPV-42 (n=140; 5%), 
and HPV-67 (n=139; 5%).  The five most prevalent types within multiple infections were 
HPV-16 (n=196; 25%), HPV-56 (n=135; 17%), HPV-42 (n=120; 15%), HPV-67 (n=117; 
15%), and HPV-52 (n=116; 15%)(Figure 4.1).  All HPV types were more likely to be 
detected as multiple infections rather than single infections, with the exception of untypeable 
infections (HPV-X: 37% multiple, 63% single).  
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Figure 4.1.  HPV genotype distribution of multiple and single infections, in order of 
descending prevalence 
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The number of HPV types detected within an individual ranged from 0 to 11 
infections.  The observed frequency of zero HPV infections and infection with four, five, and 
six or more HPV types were higher than expected under the assumption that infections are 
independent (two-sided p-value<0.01) (Table 4.1).  Frequencies of one or two HPV types 
were less than expected (p<0.01).  The distribution of observed high-risk genotype infections 
was similar to infection with any HPV genotype.  
 
Table 4.1.  Comparison of the observed and expected number of human papillomavirus 
(HPV) types detected 
Number of 
HPV genotypes 
Any HPV HR-HPV 
Observed Expected p-value
a
 Observed Expected p-value
a
 
0 1323 832.9 <0.01 1749 1494.3 <0.01 
1 592 1002.1 <0.01 571 909.4 <0.01 
2 349 581.1 <0.01 230 251.5 0.15 
3 194 214.6 0.15 103 41.6 <0.01 
4 111 57.3 <0.01 34 4.8 <0.01 
5 68 11.9 <0.01 11 0.4 <0.01 
≥6 65 2.2 <0.01 4 0.0 <0.01 
Mean (SD) 1.15 (1.60) 1.15 (1.05)   0.58 (0.96) 0.58 (0.74)   
Abbreviations: HR-HPV (high-risk human papillomavirus); SD (standard deviation) 
a
 Two-sided p-value calculation: For i=0 to 6+ types, let Oi be the observed number of men with i 
infections and let Ei be the expected number of men with i infections (based on 1000 simulations) 
assuming independence. For simulated data sets j=1 to 1000, let Oij be the number of men with i 
infections. Then for i=0 to 6+ types, the two-sided p-value was calculated as proportion of simulated 
data sets where |Oij-Ei| >= |Oi-Ei|  
 
 
Multiple HPV infections were more common among men who were younger, bathed 
less often than daily, and had chlamydia infection.  Men were less likely to have multiple 
versus single HPV type infections if they were older, or reported consistent condom use in 
the previous 6 months (Table 4.2).  The strongest positive correlate of multiple HPV 
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infections was bathing less often then daily (adjusted OR: 2.1(1.0, 4.4) vs. daily bathing).  In 
contrast, men who reported always using a condom in the previous 6 months had a 30% 
lower odds of multiple HPV infections (adjusted OR: 0.7 (0.5, 0.9) versus inconsistent users). 
Table 4.2.  Correlates multiple HPV infections among 1,379 men with HPV infection at 
baseline 
  
Single HPV                  
[N(%) or 
Median(IQR)] 
Multiple HPV             
[N(%) or 
Median(IQR)] uOR (95% CI) aOR (95% CI)
a
 
Age (years) 21 (19-22) 20 (19-22)  0.9 (0.9, 1.0) 0.9 (0.9, 1.0)  
Recent travel to Nairobi
b
    
No 480 (81.4) 670 (85.5) ref ref 
Yes 110 (18.6) 114 (14.5)   0.7 (0.6, 1.0) 0.7 (0.5, 1.0) 
Bathing frequency     
Daily 571 (97.6) 751 (96.3) ref ref 
Less than daily 14 (2.4) 29 (3.7) 1.6 (0.8, 3.0) 2.1 (1.0, 4.4) 
Recent number sexual partners
b
  
0-1 330 (56.2) 417(53.1) ref  ref 
≥2 257 (43.8) 369 (47.0) 1.1 (0.9, 1.4) 1.1 (0.9, 1.4) 
Recent condom use
b
     
Not always 410 (76.2) 590 ( 82.9) ref ref  
Always 128(23.8) 122 ( 17.1) 0.7 (0.5, 0.9) 0.7 (0.5, 0.9) 
N. gonorrhea     
No 565 (98.1) 754 (96.7) ref ref 
Yes 11 (1.9) 26 (3.3) 1.8 (0.9, 3.6)  1.9 (0.9, 4.2) 
C. trachomatis     
No 551 (95.8) 723 (92.7) ref ref  
Yes 24 (4.2) 57 (7.3) 1.8 (1.1, 3.0) 1.7 (1.0, 2.8) 
Abbreviations: IQR (inter-quartile range); uOR (unadjusted odds ratio); CI (confidence interval); aOR 
(adjusted odds ratio); ref (reference category for the odds ratio) 
Missing data: travel to Nairobi (n=5), bathing frequency (n=14), number of partners in last 6 months 
(n=6), condom use in last 6 months (men reporting no sex in last 6 months included in always 
category; n=129), . gonorrhea (n=23), C.  trachomatis (n=24) 
a
Estimates are adjusted for all potential correlates 
b
Recent refers to 6 months prior to baseline 
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In the main analysis using semi-Bayesian logistic regression, there were no negative 
associations between the four vaccine-preventable HPV types (HPV-16, 18, 6 and 11) and 
the other 41 HPV types (ORs>1.0; Table 4.3).  Although a few negative associations were 
observed in the semi-Bayes models with less precision and in the maximum likelihood 
models, all confidence intervals were wide and included the null value 1.0 (Appendix Table 
4).  There was no clear pattern of differences in HPV type associations within or across HPV 
clades.  HPV-16 was positively associated with 17 of the 41 non-vaccine HPV types (range 
of adjusted ORs: 1.7 to 3.6).  Men with HPV-16 infection were 3.6 times as likely to also be 
infected with HPV-40 compared to men without HPV-16 infection (Table 4.3; adjusted OR: 
3.6(2.4, 5.2)).  HPV-18 was positively associated with 33 non-vaccine types (range of 
adjusted ORs: 1.8 to 4.3), and had the strongest association with HPV-26 (adjusted OR: 
4.3(2.1, 7.7)).  For the vaccine-preventable low-risk types 6 and 11, 12 non-vaccine HPV 
types were positively associated with HPV-6, and 14 HPV types were positively associated 
with HPV-11.  HPV-52 was most strongly associated with HPV-6 (adjusted OR: 3.4 (2.1, 
5.3)) and HPV-45 was most strongly associated with HPV-11(adjusted OR: 2.8 (1.5, 4.9)).   
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Table 4.3.  Estimated odds ratios between the four vaccine-preventable HPV types and 
all other non-vaccine HPV types among all men 
  
HPV-16 
aOR (95% CI)
a
 
HPV-18 
aOR (95% CI)
a
 
HPV-6 
aOR (95% CI)
a
 
HPV-11 
aOR (95% CI)
a
 
Clade A3   
HPV-61 2.2 (0.9, 4.5) 2.7 (1.1, 5.5) 2.0 (0.8, 4.0) 2.3 (0.9, 4.7) 
HPV-72 2.7 (1.3, 4.8) 2.6 (1.2, 4.9) 1.8 (0.8, 3.4) 2.7 (1.2, 5.2) 
HPV-81 1.7 (1.0, 2.8) 2.4 (1.2, 4.0) 2.8 (1.5, 4.7) 1.8 (0.8, 3.3) 
HPV-83 1.8 (0.9, 3.0) 2.8 (1.4, 5.0) 1.9 (0.9, 3.5) 2.6 (1.2, 4.8) 
HPV-84 1.8 (0.8, 3.4) 2.2 (1.0, 4.3) 1.8 (0.8, 3.5) 2.1 (0.9, 4.3) 
HPV-89 1.7 (1.0, 2.9) 2.5 (1.3, 4.2) 1.5 (0.7, 2.8) 1.9 (0.9, 3.5) 
Clade A5   
HPV-26 1.7 (0.8, 3.1) 4.3 (2.1, 7.7) 1.7 (0.8, 3.3) 2.6 (1.1, 5.1) 
HPV-51 2.2 (1.4, 3.4) 1.8 (1.0, 3.1) 2.1 (1.1, 3.6) 1.8 (0.9, 3.2) 
HPV-69 2.5 (1.4, 4.2) 2.8 (1.4, 5.0) 1.9 (0.9, 3.6) 1.8 (0.8, 3.4) 
HPV-82 1.5 (0.7, 2.7) 2.3 (1.0, 4.3) 1.8 (0.8, 3.5) 2.7 (1.2, 5.2) 
Clade A6   
HPV-53 2.6 (1.3, 4.6) 2.3 (1.0, 4.2) 1.8 (0.8, 3.4) 2.3 (1.0, 4.5) 
HPV-56 2.1 (1.4, 3.0) 1.9 (1.1, 2.9) 2.9 (1.8, 4.3) 2.4 (1.3, 3.9) 
HPV-66 2.0 (1.3, 3.0) 2.3 (1.3, 3.5) 1.8 (1.0, 2.9) 1.7 (0.8, 2.9) 
Clade A7   
HPV-39 2.1 (1.2, 3.4) 2.2 (1.1, 3.9) 2.0 (1.0, 3.5) 2.4 (1.1, 4.4) 
HPV-45 1.7 (1.1, 2.6) 2.9 (1.7, 4.6) 2.0 (1.1, 3.3) 2.8 (1.5, 4.9) 
HPV-59 2.3 (1.5, 3.5) 2.9 (1.7, 4.6) 1.7 (0.9, 2.9) 2.4 (1.2, 4.2) 
HPV-68 1.3 (0.7, 2.2) 2.1 (1.0, 3.9) 1.6 (0.7, 2.9) 2.1 (0.9, 4.0) 
HPV-70 1.6 (0.9, 2.6) 1.7 (0.9, 3.0) 1.3 (0.6, 2.4) 2.0 (1.0, 3.8) 
Clade A9   
HPV-31 2.9 (1.9, 4.2) 2.8 (1.6, 4.4) 1.6 (0.8, 2.7) 1.8 (0.9, 3.2) 
HPV-33 1.9 (1.0, 3.1) 2.6 (1.3, 4.5) 1.4 (0.7, 2.6) 2.5 (1.1, 4.6) 
HPV-35 2.5 (1.6, 3.7) 1.9 (1.1, 3.1) 2.4 (1.4, 3.9) 2.0 (1.0, 3.4) 
HPV-52 1.7 (1.1, 2.5) 2.3 (1.3, 3.6) 3.4 (2.1, 5.3) 1.9 (1.0, 3.3) 
HPV-58 2.6 (1.7, 3.9) 2.3 (1.3, 3.6) 1.7 (0.9, 2.8) 1.9 (0.9, 3.2) 
Clade A10   
HPV-44 2.1 (0.9, 4.2) 2.7 (1.1, 5.5) 2.0 (0.8, 4.0) 2.3 (0.9, 4.6) 
HPV-55 1.5 (0.8, 2.6) 2.0 (1.0, 3.5) 2.6 (1.3, 4.5) 2.6 (1.2, 4.8) 
Clade A11   
HPV-34 2.0 (0.9, 4.0) 3.1 (1.3, 6.3) 2.0 (0.8, 4.1) 2.3 (0.9, 4.6) 
HPV-64 2.1 (0.9, 4.2) 2.7 (1.1, 5.5) 2.0 (0.8, 4.0) 2.3 (0.9, 4.6) 
HPV-73 2.2 (1.2, 3.5) 3.0 (1.6, 5.1) 2.0 (1.0, 3.6) 2.3 (1.1, 4.2) 
Other   
HPV-30 1.7 (0.9, 2.9) 3.1 (1.5, 5.3) 1.7 (0.8, 3.1) 2.3 (1.0, 4.3) 
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HPV-32 1.7 (0.9, 2.9) 2.3 (1.1, 4.0) 2.4 (1.2, 4.3) 2.3 (1.0, 4.3) 
HPV-40 3.6 (2.4, 5.2) 2.2 (1.3, 3.5) 2.0 (1.1, 3.3) 2.4 (1.2, 4.2) 
HPV-42 2.1 (1.4, 3.0) 2.3 (1.3, 3.6) 2.0 (1.2, 3.2) 2.6 (1.4, 4.4) 
HPV-43 1.7 (1.1, 2.6) 2.3 (1.3, 3.7) 3.0 (1.7, 4.8) 2.0 (1.0, 3.6) 
HPV-54 1.4 (0.7, 2.6) 2.6 (1.2, 4.7) 1.8 (0.8, 3.4) 2.0 (0.9, 3.9) 
HPV-57 2.2 (0.9, 4.5) 2.7 (1.1, 5.5) 2.0 (0.8, 4.0) 2.3 (0.9, 4.7) 
HPV-67 2.4 (1.6, 3.4) 1.8 (1.1, 2.9) 2.6 (1.5, 4.1) 2.0 (1.0, 3.5) 
HPV-71 2.2 (0.9, 4.5) 2.7 (1.1, 5.5) 2.0 (0.8, 4.0) 2.3 (0.9, 4.7) 
HPV-85 2.0 (0.9, 3.8) 2.8 (1.2, 5.6) 2.1 (0.9, 4.3) 2.2 (0.9, 4.5) 
HPV-86 1.8 (0.9, 3.4) 3.2 (1.5, 6.1) 1.7 (0.7, 3.2) 2.4 (1.0, 4.7) 
HPV-JC9710 1.8 (1.1, 2.6) 2.8 (1.7, 4.3) 1.5 (0.8, 2.5) 2.1 (1.1, 3.7) 
            HPV-X  1.2 (0.8, 1.8) 1.7 (1.0, 2.7) 1.7 (1.0, 2.7) 1.3 (0.6, 2.3) 
Abbreviations: aOR (adjusted odds ratio); CI (confidence interval) 
a
Odds ratios for pair-wise associations are adjusted for age, travel to Nairobi (in 6 months), bathing 
frequency, number of sexual partner (in 6 months), consistent condom use (in 6 months), and current 
Gonorrhea and C. trachomatis infection 
 
 
Results from models including only HPV16 and HPV18 as the vaccine preventable 
types were almost identical to the four vaccine type models (Appendix Table 5).  Additional 
positive associations between low-risk types HPV-6 and HPV-11 with HPV-16 and HPV-18 
were observed.  When analyses were restricted to HPV-positive men, point estimates tended 
to be closer to the null, and HPV type associations appeared not to differ within or across 
HPV clades (Table 4.4).  HPV-40 (adjusted OR: 2.1 (1.4, 2.9)) and HPV-26 (adjusted OR: 
3.4 (1.7, 5.8) remained the HPV types most strongly associated with HPV-16 and HPV-18, 
respectively.  
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Table 4.4.  Estimated odds ratios between the four vaccine-preventable HPV types and 
all other non-vaccine HPV types among men with at least one HPV infection 
  
HPV-16 
aOR (95% CI)
a
 
HPV-18 
aOR (95% CI)
a
 
HPV-6 
aOR (95% CI)
a
 
HPV-11 
aOR (95% CI)
a
 
Clade A3   
HPV-61 2.1 (0.9, 4.4) 2.8 (1.1, 5.8) 2.1 (0.8, 4.2) 2.3 (1.0, 4.8) 
HPV-72 2.1 (1.0, 3.6) 2.3 (1.1, 4.3) 1.6 (0.7, 3.1) 2.4 (1.1, 4.7) 
HPV-81 1.1 (0.7, 1.8) 1.7 (0.9, 2.8) 2.0 (1.1, 3.3) 1.5 (0.7, 2.6) 
HPV-83 1.2 (0.7, 2.0) 2.1 (1.1, 3.7) 1.6 (0.8, 2.8) 2.2 (1.1, 4.0) 
HPV-84 1.5 (0.7, 2.7) 2.0 (0.9, 3.8) 1.6 (0.7, 3.0) 2.0 (0.9, 3.9) 
HPV-89 1.2 (0.7, 1.8) 1.8 (1.0, 3.0) 1.2 (0.6, 2.1) 1.6 (0.8, 2.8) 
Clade A5   
HPV-26 1.3 (0.7, 2.2) 3.4 (1.7, 5.8) 1.5 (0.7, 2.8) 2.3 (1.1, 4.4) 
HPV-51 1.3 (0.8, 2.0) 1.3 (0.7, 2.1) 1.5 (0.8, 2.4) 1.4 (0.7, 2.4) 
HPV-69 1.8 (1.0, 2.8) 2.2 (1.1, 3.7) 1.6 (0.8, 2.8) 1.6 (0.7, 2.9) 
HPV-82 1.2 (0.6, 2.2) 1.9 (0.9, 3.6) 1.6 (0.7, 3.0) 2.4 (1.1, 4.6) 
Clade A6   
HPV-53 1.9 (1.0, 3.4) 1.9 (0.9, 3.5) 1.6 (0.7, 3.0) 2.1 (1.0, 4.0) 
HPV-56 1.2 (0.8, 1.6) 1.2 (0.7, 1.8) 1.8 (1.1, 2.6) 1.7 (0.9, 2.7) 
HPV-66 1.1 (0.8, 1.6) 1.5 (0.9, 2.2) 1.2 (0.7, 1.8) 1.2 (0.6, 2.1) 
Clade A7   
HPV-39 1.4 (0.8, 2.2) 1.7 (0.9, 2.9) 1.5 (0.8, 2.6) 2.0 (1.0, 3.6) 
HPV-45 1.1 (0.7, 1.6) 1.9 (1.1, 3.0) 1.4 (0.8, 2.2) 2.1 (1.1, 3.5) 
HPV-59 1.4 (0.9, 2.1) 2.0 (1.2, 3.1) 1.2 (0.7, 2.0) 1.8 (0.9, 3.1) 
HPV-68 0.9 (0.5, 1.6) 1.7 (0.8, 2.9) 1.3 (0.6, 2.3) 1.8 (0.8, 3.2) 
HPV-70 1.0 (0.6, 1.6) 1.3 (0.7, 2.2) 1.0 (0.5, 1.8) 1.7 (0.8, 3.0) 
Clade A9   
HPV-31 1.7 (1.1, 2.4) 1.9 (1.1, 3.0) 1.1 (0.6, 1.9) 1.4 (0.7, 2.4) 
HPV-33 1.3 (0.7, 2.0) 1.9 (1.0, 3.2) 1.2 (0.6, 2.1) 2.0 (1.0, 3.6) 
HPV-35 1.4 (0.9, 2.1) 1.3 (0.8, 2.1) 1.6 (1.0, 2.5) 1.5 (0.8, 2.5) 
HPV-52 1.0 (0.6, 1.4) 1.5 (0.9, 2.3) 2.1 (1.3, 3.2) 1.4 (0.8, 2.5) 
HPV-58 1.5 (1.0, 2.2) 1.6 (0.9, 2.4) 1.2 (0.7, 1.9) 1.5 (0.7, 2.5) 
Clade A10   
HPV-44 2.0 (0.8, 4.1) 2.7 (1.1, 5.5) 2.0 (0.8, 4.0) 2.3 (0.9, 4.8) 
HPV-55 1.1 (0.6, 1.8) 1.5 (0.8, 2.7) 2.0 (1.0, 3.4) 2.1 (1.0, 3.9) 
Clade A11   
HPV-34 1.9 (0.8, 3.9) 3.1 (1.3, 6.3) 1.9 (0.8, 3.8) 2.3 (0.9, 4.7) 
HPV-64 2.0 (0.8, 4.1) 2.7 (1.1, 5.5) 2.0 (0.8, 4.0) 2.3 (0.9, 4.8) 
HPV-73 1.4 (0.8, 2.3) 2.2 (1.2, 3.6) 1.6 (0.8, 2.6) 1.9 (0.9, 3.4) 
Other   
HPV-30 1.2 (0.7, 2.0) 2.3 (1.2, 3.9) 1.4 (0.7, 2.4) 1.9 (0.9, 3.5) 
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HPV-32 1.2 (0.7, 2.0) 1.7 (0.9, 3.0) 1.9 (0.9, 3.2) 1.9 (0.9, 3.6) 
HPV-40 2.1 (1.4, 2.9) 1.6 (0.9, 2.5) 1.4 (0.8, 2.3) 1.8 (1.0, 3.1) 
HPV-42 1.2 (0.8, 1.7) 1.5 (0.9, 2.2) 1.3 (0.8, 2.0) 1.9 (1.0, 3.0) 
HPV-43 1.0 (0.7, 1.5) 1.5 (0.9, 2.4) 2.0 (1.2, 3.0) 1.5 (0.8, 2.6) 
HPV-54 1.1 (0.6, 2.0) 2.1 (1.0, 3.9) 1.5 (0.7, 2.9) 1.8 (0.8, 3.4) 
HPV-57 2.1 (0.9, 4.4) 2.8 (1.1, 5.8) 2.1 (0.8, 4.2) 2.3 (1.0, 4.8) 
HPV-67 1.3 (0.9, 1.9) 1.2 (0.7, 1.9) 1.7 (1.0, 2.5) 1.5 (0.8, 2.5) 
HPV-71 2.1 (0.9, 4.4) 2.8 (1.1, 5.8) 2.1 (0.8, 4.2) 2.3 (1.0, 4.8) 
HPV-85 1.8 (0.8, 3.4) 2.6 (1.2, 5.2) 2.0 (0.9, 4.0) 2.1 (0.9, 4.2) 
HPV-86 1.5 (0.7, 2.8) 2.7 (1.3, 5.2) 1.5 (0.7, 2.9) 2.2 (1.0, 4.3) 
HPV-JC9710 1.0 (0.7, 1.5) 1.8 (1.1, 2.7) 1.0 (0.6, 1.6) 1.6 (0.8, 2.6) 
            HPV-X  0.7 (0.4, 0.9) 1.1 (0.6, 1.7) 1.1 (0.6, 1.6) 0.9 (0.5, 1.6) 
Abbreviations: aOR (adjusted odds ratio); CI (confidence interval) 
a
Odds ratios for pair-wise associations are adjusted for age, travel to Nairobi (in 6 months), bathing 
frequency, number of sexual partner (in 6 months), consistent condom use (in 6 months), and current 
Gonorrhea and C. trachomatis infection 
 
Discussion 
Half of all uncircumcised, HIV-negative men in this study from Kenya were infected 
with at least one HPV type at baseline.  Nearly 30% of surveyed men had multiple penile 
HPV type infections, with HPV-16 and 18 accounting for over 25% of all infections.  If  
prevalent carcinogenic HPV 16 and 18 infections were prevented by mass vaccination, there 
is a theoretical possibility that this could result in other HR-HPV types filling the ecological 
niche of HPV-16 and/or 18[64].  Since there are reported differences in genotype distribution 
across gender and geographical regions[12, 14, 65], the potential for HPV type replacement 
could differ across study populations.  The present study represents the first detailed 
investigation of multiple HPV infections and type associations within a cohort of young men 
from Africa.  Using a cross-sectional study design, we did not find any negative associations 
between vaccine-preventable types HPV 16, 18, 6 and 11 and 41 non-vaccine preventable 
HPV types.  
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All HPV genotypes were more likely to be detected as multiple rather than single type 
infections.  Further, all associations between HPV types were positive, suggesting that men 
who become infected are more likely to have more than one HPV infection, possibly due to 
behavioral or immunological factors[35, 42, 55].  When analyses were restricted to HPV-
infected men, associations between specific HPV types generally shifted closer towards 1.0, 
suggesting that specific HPV types are not associated with one another.  We also observed a 
higher number of men than expected with four or more HPV type infections, suggesting that 
individual HPV infections were not independent from each other.  This is likely due to the 
fact that men with four or more HPV infections reported less condom use in the last 6 months 
and more lifetime partners as compared to men with 1-3 HPV infections.  These observations 
represent, to our knowledge, the first of their kind among men, and are consistent with results 
from studies among women [58-60].  Numerous prospective studies have found that women 
with HPV infection at baseline are more likely to acquire additional HPV types[35, 40, 42, 
43, 55] and that acquisition of multiple HPV types occurs more often than expected[35, 41, 
42].   It is likely that the observed pattern of number and types of HPV infections reflect 
differences in HPV persistence or acquisition in men. 
Positive associations between HPV types were observed yet appeared not to be type-
specific.  Our results among Kenyan men are consistent with a prospective study of 
American female college students that found no two HPV types are more likely to be 
acquired together than any other HPV types[42].  Most studies that have examined HPV type 
associations in women have reported positive or no associations between HPV types, 
regardless of the pair-wise combinations, analytical methods, HPV genotyping methods, or 
study population[42, 59].  However, among female colposcopy clinic attendees in Italy, 
59 
 
where the genotype distribution likely differs compared to the general population, co-
infection with species A7 and A10 and with HPV-31 and 52 occurred less often than 
expected[61].  A large cross-sectional study of Danish women referred for testing based on 
clinical suspicion of infection found that HPV-51 was negatively associated with HPV-
16[60].   
In this large sample of men with an HPV prevalence of 50%, we had the ability to 
look at type-type associations, even for rarer HPV types, using semi-Bayesian methods that 
incorporated a shrinkage factor.  We chose Bayesian methods to account for all vaccine types 
and covariates while reducing spurious associations.  There is, however, a trade-off between 
precision and bias in methods that incorporate a shrinkage factor[77].  We therefore 
conducted sensitivity analyses to understand the effect of our statistical model choices and to 
compare our results with other studies that used maximum likelihood estimation[58-60].  
Different methods to analyze our data resulted in wider confidence intervals and, in some 
cases, non-significant ORs less than 1.0.  However, all methods resulted in the same 
conclusions regarding the lack of evidence of negative associations between prevalent HPV 
type infections in men.  Like previous studies[58-61], we made multiple comparisons across 
outcomes, which can increase the possibility of falsely concluding certain HPV types are 
associated.  By including all four vaccine types in each of our models, the number of 
comparisons was reduced compared to other pair-wise analyses[58-61].  
In the present study, we could only determine if the number and type of HPV 
infections were independent.  The causes of non-independence may be differences in host 
susceptibility, the type-distribution of HPV genotypes in female sexual partners and 
circulating in the general population, or molecular interactions between HPV types that 
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inhibit infection with other HPV types (type competition).  Although we were able to control 
for several measured confounders, it is likely that there is residual confounding by other 
unmeasured behavioral risk factors, immunological differences between men[35, 42] and 
HPV type exposure from female sexual partners.  In populations where negative associations 
between HPV types are observed, molecular studies and prospective studies of couples are 
needed to address whether these associations are likely due to type competition. 
Our study has additional limitations to consider when interpreting the findings.  The 
prevalence and the type distribution of HPV has been shown to differ by circumcision status, 
thus the results from this cohort of uncircumcised men may not be generalizable to 
circumcised populations[34, 52].  In addition, no participants received HPV prophylactic 
vaccination, so we could only observe differences between individuals who were naturally 
HPV uninfected and infected with HPV-16, 18, 6 and 11.  Given the cross-sectional design, it 
is also not known whether infection with specific HPV types affects HPV acquisition or HPV 
persistence of additional HPV types.   
With the recent approval of HPV vaccination in men[66], these data fill an important 
gap in our knowledge on the distribution and associations between HPV types in multiple 
infections among men.  Future prospective studies in populations pre- and post-vaccination 
are needed to observe the natural history of multiple infections and assess the long-term 
potential for HPV type replacement. 
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V: TYPE-SPECIFIC ASSOCIATIOS BETWEE  
PREVALET HPV IFECTIOS AD FUTURE  
ACQUISITIO OF HIGH-RISK HPV TYPES I ME 
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Abstract 
Background: Data in men are limited on type-specific associations between prevalent HPV 
infections and risk of acquiring other HPV types.   
 
Methods: Using data from a randomized control trial of male circumcision in Kisumu, 
Kenya, adjusted hazard ratios (aHRs) were estimated for type-specific acquisition of any 
other HPV, high-risk (HR), and individual HPV types among uncircumcised men infected as 
compared to uninfected with HPV-16, 18, 31, 45, 6 or 11 at baseline.   
 
Results: Among 1,064 uncircumcised men, 50% had penile HPV infections at baseline.  Men 
with HPV-18, 31, 45, or 11, but not HPV-16 or 6, had higher rates of acquisition of any other 
HPV types and other HR-HPV types than men without these HPV types at baseline.  
Acquisition of individual HR-HPV types varied by baseline HPV type; however, we did not 
observe a pattern of HPV acquisition by degree of phylogenetic relatedness to the baseline 
infection.  Except for HPV-39 among men with HPV-6 at baseline (aHR: 0.1 (0.0, 0.8)), 
there was no evidence of reduced HPV acquisition of any specific HPV type among men 
with HPV at baseline.   
 
Conclusions: Post-vaccination surveillance studies are needed to definitely determine if 
prevention of HPV types by prophylactic vaccination will alter the distribution of HPV types 
in the population. 
 
 
63 
 
Introduction 
Human papillomavirus (HPV) infection is the primary cause of cervical cancer in 
women[3, 86].  Other genital cancers, including vaginal, vulvar, anal, and penile carcinoma 
are also caused by HPV infection.  Multiple HPV types have been detected in 20-73% of 
HPV infected males[14, 32-39] and are important for the risk of transmission to female 
sexual partners and development of anogenital cancers.  With the recent approval of 
prophylactic HPV vaccination of young men[66], data are needed to understand if patterns of 
HPV acquisition differ among men with specific HPV type infections as compared to men 
without these HPV infections.  The effect of current HPV infections on the acquisition of 
different HPV types could impact the long-term potential for HPV type replacement 
following population-based HPV vaccination[41, 64].   
Previous studies have shown that infection with multiple HPV types occurs more 
often than expected if the infections were independent[41, 42, 58-60].  Women with HPV 
infection at baseline are more likely to acquire additional HPV types than those 
uninfected[35, 40, 42, 43, 55].  In analyses limited to five HPV types, DNA detection of 
either HPV-16, 18, 31, 45 or 6 did not predict acquisition of any of the other four specific 
HPV types among female University students[42].  In contrast, incident infections with HPV-
16 and 18 were associated with higher odds of acquiring HPV-58, but not 5 other HPV types, 
among cytologically normal women from Colombia[41].  In a population of cytologically 
normal women from the United States[43] and in the ASCUS/LSIL Triage Study[55], all 
HPV infections, regardless of type, were associated with higher acquisition rates of other 
HPV types, as compared to being uninfected, likely due to a common mode of transmission 
or shared risk factors. 
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There are differences in the natural history of type-specific HPV infections between 
women and men[12, 65].  However, no prospective studies in men have examined the 
associations between specific HPV types over time.  Therefore, we aim here to compare rates 
of grouped (overall, high-risk) and type-specific acquisition of 14 high-risk (HR) HPV types 
among men DNA positive as compared to DNA negative for type-specific HPV-16, 18, 31, 
45, 6 or 11 infections at baseline, using data from a longitudinal cohort of young, 
uncircumcised men from Kisumu, Kenya.  
 
Methods 
Study population and design 
A randomized controlled trial (RCT) was conducted in Kisumu, Kenya in 2002-2006 
to determine the effectiveness of male circumcision in reducing the incidence of HIV 
infection[67].  A cohort study on the natural history of HPV infections in men was nested in 
the RCT[32, 68, 69].  Briefly, eligible males were between 18-24 years old, uncircumcised, 
HIV seronegative, and sexually active.  Of the 2,702 men screened for participation in the 
RCT, 2,228 were enrolled. The present study is a longitudinal analysis of uncircumcised, 
HIV-seronegative men who were randomized to the delayed circumcision (control) arm of 
the RCT (n=1,102) and had HPV DNA results at baseline and at least one follow-up visit 
(n=1,064).  
Study visits were conducted every 6 months for 24 months of follow-up.  At baseline 
and each biannual visit, trained male interviewers administered a standardized questionnaire 
on socio-demographic characteristics, sexual behavior and other medical conditions.  A 
trained physician or clinical officer conducted a physical exam during which a urine sample 
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was collected for PCR detection of C. trachomatis (Roche Diagnostics).  For HPV DNA 
detection, penile exfoliated cells were collected from 2 anatomical sites using prewetted 
Dacron swabs and stored in two separate tubes: i) the shaft and external foreskin tissue and 
ii) the glans, coronal sulcus and inner foreskin tissue[69].  All participants provided informed 
consent and all study protocols were approved by the Institutional Review Boards at each 
collaborating university. 
 
Detection of HPV DA 
DNA was isolated from exfoliated penile cell samples[70, 71] and the presence of 
human DNA was evaluated by beta-globin-specific polymerase chain reaction (PCR).  HPV 
DNA was assessed by GP5+/6+ PCR, followed by hybridization of PCR products using an 
enzyme immunoassay readout with two HPV oligoprobe cocktail probes that together detect 
44 HPV types.  Subsequent HPV genotyping was performed by reverse line blot 
hybridization of the PCR products, as described previously[70, 71].  HPV types 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were classified as HR-HPV types, and the other 
30 HPV types were categorized as low-risk (LR) HPV.  HPV types within the same 
phylogenetic clade were considered genetically-related and HPV types across different clades 
were considered unrelated[87].  HPV types detected by enzyme immunoassay, but not by 
reverse line blot genotyping, were designated as HPV X and were not included in either the 
high- or low-risk categories.  HPV detection was performed on the shaft and glans samples 
separately; we present here the pooled HPV DNA results from both anatomical sites 
combined.   
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Statistical analysis 
The main exposure of interest was a baseline infection with HPV-16, 18, 31, 45, 6 or 11 as 
compared to men without each individual type at baseline.  HPV types 16, 18, 6 and 11 were 
chosen as baseline types of interest due to their inclusion in current generation HPV 
prophylactic vaccines[7, 9].  Given the relatively high prevalence of HPV 45 in 
adenocarcinoma and the potential for HPV cross-protection against HPV-31[10], we also 
investigated associations between HPV types 31 and 45 and future HPV acquisition.  The 
study outcomes were time to acquisition of all other HPV types except the baseline type of 
interest, any other HR-HPV infection, and acquisition of each one of the other 13 HR-HPV 
types.  For example, in the analysis of HPV-16 baseline infection status, we investigated 
acquisition of all other HPV types except HPV-16 and acquisition of all HR-HPV types 
except HPV-16.  For all analyses, type-specific HPV acquisition was defined as the detection 
of a new HPV genotype at the current visit that was not detected at any of the previous study 
visits.  Men could be simultaneously infected with multiple HPV types at any given time-
point since infection with one type was not considered a competing risk for infection with 
another type. 
Time to first infection for each HPV type was analyzed using interval censored 
survival methods because the time of acquisition was not directly observed, rather acquisition 
events were only known to have occurred between the last HPV negative visit and the first 
HPV positive visit[80].  If men crossed-over to the circumcision arm during the study 
(N=50), they were right-censored at their last visit with HPV DNA results prior to 
circumcision.  For each HPV type where an acquisition was not observed, the data were 
right-censored at the final study visit.  If HPV DNA results were missing for the visit(s) 
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before the first HPV positive visit, the acquisition interval spanned from the last non-missing 
HPV negative visit to the first HPV positive visit.  If a result was missing between two HPV 
negative visits, then the missing value was assumed to be HPV negative.  When this 
assumption was evaluated by changing the missing values from HPV negative to HPV 
positive, there was a minimal effect on the aHRs for HPV acquisition (data not shown). 
Unadjusted survival curves were used to graphically display the pattern of HPV 
acquisition, stratified by HPV-16, 18, 31, 45, 6 and 11 DNA status at baseline.  The survival 
function, which describes the probability of not acquiring an HPV infection as a function of 
time, was estimated using the nonparametric maximum likelihood estimator[83, 84], which is 
the general form of the Kaplan-Meier estimator for interval censored data.  We used the 
published SAS macro %ICE to estimate the survival function, which is appropriate for data 
that are arbitrarily censored with varying interval widths[80]. 
Parametric frailty survival models were used to estimate the overall association 
between type-specific infections at baseline and acquisition of any-HPV and HR-HPV except 
the baseline HPV type of interest.  Parametric frailty models account for the correlation 
between HPV types among men with multiple infections[81] and allow for interval censored 
data.  Survival times were assumed to follow a Weibull distribution, such that the model can 
be viewed as either an accelerated failure time model or a proportional hazards model[81, 
82].  The models were parameterized such that an adjusted hazard ratio (aHR) less than 1.0 
indicates a lower rate of HPV acquisition among men positive for a specific HPV type 
compared to men negative for that same type at baseline, adjusted for potential confounding 
variables.  The adjusted median survival ratio (aMSR) compares the median time to HPV 
acquisition among HPV infected versus uninfected men at baseline, adjusted for potential 
68 
 
confounding variables.  Parametric survival models without the random effects frailty term 
were used to estimate the aHR for the association between HPV types at baseline and 
acquisition of each individual HR-HPV type. 
All models were adjusted for potential confounding variables that were identified in 
the literature and our previous analysis of multiple HPV infections in this cohort, including 
baseline age (centered at 20 years), number of sexual partners (in 6 months prior to baseline), 
consistent condom use (in 6 months prior to baseline), as well as bathing frequency and 
baseline C. trachomatis infection, which were previously shown to be associated with 
multiple HPV infections in this cohort (Rositch et al (2011); submitted to JID).  Analysis and 
interpretation of study results were based on patterns of type-specific HPV acquisition, 
defined by the magnitude and precision (95% confidence interval) of the estimates, rather 
than on statistical significance. 
 
Results 
The median age of the 1,064 men with baseline and at least one follow-up visit was 
20 years (inter-quartile range [IQR] 19-22) (Table 5.1).  Most men in the study population 
were not married (94%), unemployed (52%), and had 11 years of education (IQR: 8-12).  
The median age at sexual debut was 16 years (IQR: 14-17) and over half of men reported 0-1 
sexual partners in the previous 6 months (57%).  Consistent condom use in the previous 6 
months was reported by roughly a quarter of men (23%) and C. trachomatis was detected in 
4% of men at baseline.  Nearly 70% of men had HPV DNA results available at all 5 study 
visits, with a median duration of 184 days (IQR: 183-187) between visits. 
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Table 5.1.  Baseline characteristics of the uncircumcised, HIV-negative male study 
population (=1,064)  
  Study population 
N (%) or Median (IQR)
a
 
Age in years 20 (19-22) 
Marital status 
Not married 1000 (94.4) 
Married 59 (5.6) 
Employment status 
Unemployed 554 (52.3) 
Employed 506 (47.7) 
Years of education 11 (8-12) 
Bathing frequency 
Less than daily 21 (2.0) 
Daily 1030 (98.0) 
Age at sexual debut 16 (14-17) 
Number of sexual partners (6 months) 
0-1 Partners 599 (56.5) 
≥ 2  partners 461 (43.5) 
Condom use (6 months) 
Not always 731 (77.0) 
Always 218 (23.0) 
C. trachomatis infection 
No 1010 (96.0) 
Yes 42 (4.0) 
Length of testing interval (days) 184 (183-187)  
Number of visits per person 5 (4-5) 
Abbreviations: N (number); % (percentage); IQR (inter-quartile range) 
a
Missing: marital status (n=5), employment status (n=4), bathing frequency (n=13), age at sexual 
debut (n=4), Number of partners (n=4), condom use (“always” category includes men reporting no 
sex in last six month; n=115), C. trachomatis (n=12) 
 
 
At baseline, 50% of men were HPV-infected, with multiple infections (n=304; 29%) 
detected more often than single HPV infections (n=227; 21%; p<0.01) (Table 5.2).  The 
prevalence of baseline types of interest ranged from 10% for HPV-16 (n=101) to 2% for 
HPV-11 (n=19).  During follow-up, the prevalence of overall HPV ranged from 49% (n=462 
at 18 months) to 41% (n=366 at 24 months) and the median number of types among men 
70 
 
with detectable HPV was 2 (range: 1-15).  A total of 127 men (12%) had no detectable HPV 
at all study visits.  Beta-globin was detected in 72% of all penile samples (range per visit: 63-
85%).  The prevalence of HPV among beta-globin positive samples was very similar to the 
prevalence in the entire cohort, for example, 670 beta-globin positive baseline samples had 
an HPV prevalence of  52% (n=347; data not shown), compared to 50% at baseline. 
A total of 2,233 HPV infections were acquired over study follow-up, of which 1,108 
were HR-HPV types (Table 5.3). The most commonly acquired types were HPV-16 (n=178), 
HPV-56 (n=118), HPV-35 (n=107), HPV-42 (n=100), HPV-6 (n=97).  In parametric frailty 
models, the rate of acquisition of any other HPV and other HR-HPV infections were higher 
among men with HPV-18, 31, 45, or 11 as compared to men without that type at baseline, 
adjusted for age, bathing frequency, condom use, number of recent sexual partners and 
presence of C. trachomatis.  Infection with HPV-16 (aHR: 1.2 (95% confidence interval [CI]: 
0.9, 1.6)) or HPV-6 (aHR: 1.4 (0.9, 2.1)) was not associated with higher rates of HPV 
acquisition.  The median time to overall HPV acquisition among men with HPV-18 (aMSR: 
2.2 (1.4, 3.5)) or HPV-45 (aMSR: 2.1 (1.4, 3.1.)) was over two times that of men without 
these infections.  The same patterns of acquisition were observed for HR-HPV; however 
point estimates were closer to 1.0.  For the HPV types included in the HPV vaccines (Table 
5.3), there was an increase in any-HPV (aHR: 1.5 (1.2, 1.9)) and HR-HPV (aHR: 1.3 (1.0, 
1.8)) among men with HPV-16 and/or 18 at baseline as compared to men negative to both 
HPV-16 and 18.  Similar aHRs were observed for men with HPV-6 and/or 11 at baseline 
compared to those negative for both HPV-6 and 11, and for men with HPV-16, 18, 6 and/or 
11 compared to men without any HPV-16, 18, 6 and 11 infection.
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Table 5.5.  The associations between grouped HPV-16, 18, 6 and 11 infections at 
baseline and acquisition of individual HR-HPV types  
  Baseline HPV infection 
HPV acquisition  
HPV-16, 18
a
 
n=134 
HPV-6, 11
b 
n=53 
HPV-16, 18, 6,11
c 
n=172 
aHR(95%CI)
d
 aHR(95%CI)
d
 aHR(95%CI)
d
 
Clade A9 
HPV-16 (n=178)  N/A 1.7 (0.8, 3.4) N/A 
HPV-31 (n=56)  1.9 (0.9, 4.1) 2.8 (1.0, 7.3) 2.0 (1.0, 4.0) 
HPV-33 (n=70) 1.5 (0.9, 2.5) 1.1 (0.5, 2.6) 1.2 (0.7, 2.0) 
HPV-35 (n=107) 1.3 (0.6, 2.5) 2.2 (0.9, 5.0) 1.3 (0.7, 2.4) 
HPV-52 (n=61)  1.0 (0.5, 2.2) 1.7 (0.7, 4.4) 1.3 (0.7, 2.4) 
HPV-58 (n=76)  3.4 (1.7, 6.9) 1.9 (0.7, 4.9) 3.0 (1.6, 5.8) 
Clade A7 
HPV-18 (n=90)  N/A 1.5 (0.6, 3.4) N/A 
HPV-39 (n=49)  0.9 (0.4, 2.0) 0.1 (0.0, 1.3) 0.6 (0.3, 1.5) 
HPV-45 (n=67) 0.6 (0.3, 1.5) 1.2 (0.5, 2.9) 0.8 (0.4, 1.5) 
HPV-59 (n=56)  0.6 (0.2, 1.7) 1.1 (0.4, 3.4) 0.9 (0.4, 1.8) 
HPV-68 (n=19)  0.9 (0.2, 3.6) 1.0 (0.1, 7.8) 1.0 (0.3, 3.6) 
Clade A6 
HPV-56 (n=118)  1.1 (0.7, 1.9) 0.8 (0.3, 2.0) 1.0 (0.6, 1.7) 
HPV-66 (n=87)  1.2 (0.5, 2.5) 0.6 (0.1, 2.4) 1.1 (0.6, 2.2) 
Clade A5 
HPV-51 (n=74)  1.8 (0.9, 3.4) 1.3 (0.5, 3.3) 1.8 (1.0, 3.3) 
Abbreviations: HPV (human papillomavirus); HR (high-risk); aHR (adjusted hazard ratio); CI 
(confidence interval); N/A (not an applicable outcome type)
  
a
Vaccine-preventable high-risk types; Index group 16 and/or 18 positive vs. referent group 16 and 18 
negative 
b
Vaccine-preventable low-risk types; Index group 6 and/or 11 positive vs. referent group 6 and 11 
negative 
c
Index group 16, 18, 6, and/or 11 positive vs. referent group 16, 18, 6, and 11 negative 
d
Adjusted for age (centered at 20 years), bathing frequency, number of sexual partners (in 6 months), 
consistent condom use (in 6 months), C. trachomatis infection 
 
 
Discussion 
This study presents, to our knowledge, the first data in men on the associations 
between prevalent HPV infections and acquisition of other HPV types to assess the potential 
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for HPV type competition and replacement following wide-spread prophylactic HPV 
vaccination.  Among 1,064 uncircumcised men from Kenya, infections with HPV-18, 31, 45, 
or 11 at baseline were associated with an overall higher rate of any-HPV and HR-HPV 
infections.  Type-specific associations between baseline infections and acquisition of 
individual HR-HPV types varied greatly by HPV type; however, we did not observe a clear 
pattern in the rates of HPV acquisition by the degree of phylogenetic relatedness to the 
baseline infection.  Except for the potentially reduced acquisition of HPV-39 among men 
with HPV-6 at baseline, which was based on only one incident infection among men with 
HPV-6 at baseline, there was no clear evidence of lower rates of acquisition of specific HR-
HPV types among men with baseline HPV infection.    
To better understand which HPV types were contributing to the overall positive 
association between prevalent infections and HPV acquisition, we analyzed acquisition of the 
14 HR-HPV types in separately.  There were 53 positive associations (aHRs >1.0) among the 
80 type-specific comparisons, 6 aHRs were equal to 1.0, and 21 negative association between 
baseline HPV types and rates of type-specific acquisition (aHRs<1.).  Estimates below the 
1.0 were generally imprecise, with wide confidence intervals (minimum confidence limit 
ratio of 12.5) that included 1.0.  The wide range in estimates and corresponding 95% 
confidence intervals for type-specific HPV acquisition (aHR range: 0.1 (0.0, 0.8) for 
acquisition of HPV-39 by baseline HPV-6 status, to 4.3 (1.1, 13.1) for acquisition of HPV-35 
by baseline HPV-11 status) indicated that some, but not all, HR-HPV types had a higher rate 
of acquisition among men with baseline HPV infections.  Further, we did not observe a 
consistent pattern of HPV acquisition by HPV type or degree of phylogenetic relatedness.  
There was a trend for higher acquisition of all HR-HPV types in clade-A9 among men 
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infected with the type HPV-45 (clade A7) as compared to uninfected men.  On the other 
hand, acquisition of HR-HPV types in clade-A7 tended to be lower among men with 
unrelated type HPV-16.  Among men HPV-16 positive at baseline, acquisition of two of the 
five phylogenetically related HR-HPV types, HPV-31 and 58, were increased as compared to 
men without HPV-16 at baseline.  These findings are consistent with an analysis of the 
ASCUS/LSIL triage study, which also found a reduction in all clade-A7 types in the presence 
of HPV-16 infection and found HPV-31 to be increased among women with current HPV-16 
infection[55].   
We observed an overall trend of increased acquisition of non-vaccine-preventable 
HR-HPV among men with vaccine-included HPV types 16, 18, 6 and/or 11 as compared to 
men negative to these four types. These findings are consistent with a previous study of 
women from Colombia, which reported an increased risk of HPV-58 among women with 
HPV-16 or 18, and an increased risk of HPV-18 among women with previous HPV-6 or 11 
infections[41].  It is possible that when comparing men who are negative to all four HPV 
types to men with at least 1-4 HPV infections, the aHRs reflect differences in HPV 
acquisition by risk groups rather than differences by HPV type.  In fact, when we limited our 
analysis to men with detectable HPV during the study period (n=937), aHRs tended to be 
closer to 1.0, indicating smaller relative differences in rates of HPV acquisition between men 
with specific HPV types at baseline compared to those without each individual HPV type 
(Appendix Table 6).  
In epidemiological studies of associations between HPV types, point estimates reflect 
the combined effect of factors that may increase HPV acquisition, such as unmeasured 
behavioral risk factors or potential biological facilitation of HPV acquisition by other HPV 
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types[35, 41, 42] and factors that may decrease acquisition among men with baseline HPV 
types, such as acquired immunity[40, 42] cross-protection[41-43] or potential HPV type 
competition.  Because HPV acquisition is strongly related to sexual behavior, we adjusted all 
estimates for several potential confounding variables, including age, recent number of sexual 
partners, and consistent condom use.  There is likely residual confounding by unmeasured 
sexual risk behaviors and exposure to HPV types circulating within sexual networks.  Also, 
we examined HPV DNA positivity, not seropositivity, at baseline and acquisition of HPV 
types not previously detected in the study.  It is possible that a previous infection with a 
specific HPV type could reduce the likelihood of acquiring that type over follow-up[40, 42, 
88, 89] and this could potentially differ by baseline HPV status.  However, men in our study 
population were young (median age 20 years) with relatively few lifetime partners (median 4 
partners), both of which did not differ by baseline status to individual HPV types.   
A strength of this prospective study in men is the use of statistical models for interval 
censored HPV outcomes that include a random effects frailty term to take into account the 
correlation among acquisition of multiple HPV types[81].  In addition, there was extensive 
information on potential confounding variables, including laboratory diagnosed C. 
trachomatis, which was previously shown in this population to be associated with multiple 
HPV infections.  Despite the large sample size, a limitation of this study was the small 
number of events for select HPV types, which is reflected in the wide confidence intervals.  
In addition, the use of GP5+/6+ primers with reverse line blot hybridization likely reduces 
cross-hybridization between HPV types [58, 70]but might be relatively less likely to detect 
specific HPV types or multiple infections as compared to other detection methods[72, 73].  
An additional consideration when interpreting the study results is the restriction of our 
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sample to young, uncircumcised men.  Our findings may not be generalizable to older 
populations with a longer history of HPV exposure[40] or to circumcised males who may 
have lower rates of HPV acquisition and multiple infections[34, 52].  
Using data from a large cohort of HIV-uninfected men from Kisumu, Kenya, we 
contribute to the previous literature in women by presenting data on the associations between 
baseline HPV infections and acquisition of other HPV types in men.  Our young, male study 
population is particularly relevant given the FDA recently approved extending HPV vaccine 
coverage to males age 9 to 26 years[66].  Our data indicate that current infections are 
generally associated with a slightly higher rate of acquisition of other HPV infections.  In 
terms of type-specific findings, there were no consistently negative associations between 
specific HPV types that could indicate strong potential for HPV type replacement following 
HPV vaccination.  Ongoing vaccine surveillance studies will provide more definitive data on 
the potential for changes in the distribution of non-vaccine preventable HPV types following 
wide-spread HPV vaccination. 
 
 
  
 
VI: DISCUSSIO 
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In the 1970’s, most researchers believed that a virus could not cause cervical cancer, 
and those who did were focused on the herpes simplex virus type 2.  However, in 1983, after 
a decade of research, Dr. zur Hausen linked cervical cancer to novel human papillomavirus 
type 16, which he isolated from cervical cancer biopsies.  A year later, HPV-18 was cloned 
from biopsy specimens.  By the time Dr. zur Hausen won the Nobel Prize for Physiology and 
Medicine in 2008, it was well established that HPV-16 and HPV-18 cause 70% of cervical 
cancer cases worldwide.  The discovery of HPV as the primary cause of cervical, and many 
other anogenital cancers, spurred one of the most productive public health research efforts in 
recent history that led to rapid advances in the diagnosis, treatment and prevention of cervical 
cancer.   
In the mid-1990’s HPV DNA tests were developed and incorporated into routine 
clinical care to identify HPV in cervical Pap smears and biopsy samples.  HPV DNA tests 
have been shown to be more sensitive than Pap smears for the detection of cervical 
precancer.  In 2006, the FDA approved the first prophylactic HPV vaccine, Gardasil (Merck) 
to prevent persistent infection with HPV-16 and 18, and low-risk HPV types 6 and 11, which 
are responsible for 90% of genital warts.  In 2009, the bivalent Cervarix vaccine 
(GlaxoSmithKline) was approved for the prevention of HPV-16 and 18 and potential cross-
protection against other cancer-causing HPV types 31 and 45.  Wide-spread vaccination has 
the potential to prevent 70% of cervical cancer cases worldwide, yet there are limitations to 
HPV vaccination that require continued Pap smear screening and clinical research.  Very 
little is known about the duration of protection beyond 7 years or the need for a booster in 
women, vaccine uptake, long-term efficacy and cost-effectiveness in males, the efficacy in 
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HIV-infected individuals, and possible changes in the HPV type distribution following the 
elimination of HPV-16 and 18 by vaccination. 
 
Summary of findings 
In the cohort of men screened for participation in the RCT, 50% of uncircumcised, 
HIV-negative men were HPV-infected at baseline.  Nearly 30% of men had multiple penile 
HPV type infections, with HPV-16 and 18 accounting for over 25% of all infections.  The 
number of HPV types detected within an individual ranged from 0 to 11 infections and all 
HPV genotypes were more likely to be detected as multiple rather than single type infections.  
We observed a higher number of men with no HPV infection and with four or more HPV 
type than would have been expected if each HPV infection was independent of all others.  
This is likely due to the fact that men with four or more HPV infections reported less condom 
use in the last 6 months and more lifetime partners compared to men with 1-3 HPV 
infections. 
Using a cross-sectional study design, we did not find any negative associations 
between vaccine-preventable types HPV 16, 18, 6 and 11 and 41 non-vaccine preventable 
HPV types.  Odds ratios for all pair-wise analyses ranged from 1.2 (0.8, 1.8) to 3.4 (2.1, 5.3) 
indicating either no association between HPV types or positive associations.  HPV-16 was 
positively associated with 17 of the 41 non-vaccine HPV types (range of adjusted OR’s: 1.7 
to 3.6) and had the strongest association with low-risk HPV-40 (aOR: 3.6(2.4, 5.2)).  HPV-18 
had the most positive association (n=33 non-vaccine types; range of adjusted ORs: 1.8 to 
4.3), and had the strongest association with low-risk HPV-26 (aOR: 4.3(2.1, 7.7)).  Low risk 
HPV type 6 was positively associated with 12 non-vaccine HPV types and high-risk HPV-52 
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was most strongly associated with HPV-6 (aOR: 3.4 (2.1, 5.3)).  HPV-11 was positively 
associated with 14 HPV types and high-risk HPV-45 was most strongly associated with 
HPV-11(aOR: 2.8 (1.5, 4.9)). 
The findings of our prospective analysis were consistent with the main finding of the 
cross-sectional study: no evidence of negative associations between HPV types.  The relative 
rates of acquisition varied by both baseline type and acquisition type but there was no 
evidence, with the possible exception of HPV-39 acquisition (aHR: 0.1 (0.0, 0.8)) among 
men with HPV-6 infection at baseline, of reduced HPV acquisition of any one of the 14 HR-
HPV types among men with HPV at baseline.  Infection with HPV types 18, 31, 45, or 11, 
but not HPV-16 or 6, at baseline were associated with an overall higher rate of any-HPV 
(n=2,233) and HR-HPV (n=1,108) acquisition.  In addition, infection with at least one of the 
four vaccine-preventable HPV types compared to negative for all four HPV types was 
associated with an increased rate of any-HPV acquisition over 2,462 person-years of follow-
up.   
We did not observe a consistent pattern of association between pairs of prevalent 
HPV types or HPV acquisition by degree of phylogenetic relatedness.  For example, there 
was a trend for acquisition of all HR-HPV types in clade-A9 to be higher among men 
infected with the unrelated type HPV-45 as compared to uninfected men, yet acquisition of 
all HR-HPV types in clade-A7 tended to be lower among men with unrelated type HPV-16.  
Interestingly, HPV-16 was not associated with an overall increase in any-HPV or HR-HPV 
acquisition.  These results reflect the finding of the type-specific analyses, which showed that 
acquisition of only two HPV types was increased, while other types were not associated with 
baseline HPV-16 or had slightly negative associations.  The only negative association 
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observed between all pair-wise comparisons with a confidence interval that excluded 1.0 was 
for the acquisition of HPV-39 among men infected with HPV-6 at baseline as compared to 
uninfected (aHR: 0.1 (0.0, 0.8)); however, the sample size was small, with only one HPV-39 
acquisition among the 35 men with HPV-6 infection at baseline.   
 
Study strengths and limitations 
In this large sample of men, we had the ability to look at pair-wise associations, even 
for rare HPV types using semi-Bayesian methods.  These methods allowed us to include all 
four vaccine types and potential confounders in each model, and reduce spurious associations 
between HPV types.  Sensitivity analyses using maximum likelihood estimation and using 
semi-Bayesian methods with varying degrees of precision resulted in wider confidence 
intervals and, in some cases, non-significant ORs less than 1.0.  Reassuring, all methods 
resulted in the same general conclusion regarding the lack of evidence of strong negative 
associations between HPV types.  
The study of aim #1 raised the question as to whether the positive associations 
between types reflected differences in HPV acquisition or persistence.  In the second study, 
we found evidence of increased HPV acquisition by baseline infection; a future study will 
examine the association between prevalent infections and HPV persistence and clearance.  
Like paper one, a strength of the study was the choice of statistical methods, here the use of 
parametric frailty models that include a random effects term to account for the correlation 
between HPV types among men who acquire multiple infections[81].  Unlike the cross-
sectional study that made use of statistically powerful Bayesian methods, the prospective 
study was limited by the small number of events for specific HPV types, which is reflected in 
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the wide confidence intervals.  In addition, the use of GP5+/6+ primers with reverse line blot 
hybridization likely reduces cross-hybridization between HPV types[58, 70].  On the other 
hand, this HPV DNA detection method may be relatively less likely to detect specific HPV 
types or multiple infections as compared to other methods[72, 73].   
As discussed previously, the findings in these studies may not be generalizable to 
older men, who have longer histories of HPV exposure, or to circumcised men, who may 
have a reduced likelihood of HPV acquisition[40] and multiple infections[34, 52].  In 
addition, no participants received the HPV prophylactic vaccine, so we could only observe 
relative differences in HPV type associations and HPV acquisition among individuals who 
were naturally HPV infected and uninfected with vaccine-relevant HPV types at baseline.   
 
Interpretation and public health significance 
In epidemiological studies on HPV type associations and potential type competition,  
point estimates reflect differences in host susceptibility, sexual behavior, HPV type exposure 
from female sexual partners, and potential molecular interactions between HPV types that 
inhibit infection (type competition) or facilitate infection with other HPV types.  Thus, in the 
present study, we assessed the overall association between HPV types, after controlling for 
several behavioral confounding variables.  However, it is likely that there is residual 
confounding by other unmeasured behavioral risk factors and biological factors, both of 
which can be associated with an increase or decrease of specific HPV types in the presence 
of other HPV infections.  The distribution of individual factors and the overall balance of 
positive and negative associations likely differ across study populations and analytical 
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adjustment for confounding, which could explain the variability in results across previous 
study populations.   
In this population of young, uncircumcised men, current infection with vaccine-
relevant HPV types was generally associated with a slightly higher rate of future acquisition 
of any-other HPV and HR-HPV types, after adjustment for age and other sexual behaviors.  
In light of the caveats above, these data are reassuring as there were no consistently negative 
associations between HPV types.  Although we can in no way conclude that competition 
between HPV types does not exist, our data suggestion that at a minimum, factors that create 
positive associations between HPV types seem to outweigh or overwhelm the factors that 
may make infection with certain HPV types less likely in the presence of other HPV types.  
On a population level, where sexual behavior and immunological differences and potential 
facilitation of other infections do exist, these findings are reassuring.  Just as this research 
does not provide definitive evidence against HPV type competition, rather just insight into 
the clustering patterns of HPV genotypes over time in our study population, the findings 
highlight other important questions regarding the role of acquired immunity, cross-
protection, and infection reactivation on the long-term efficacy of the HPV vaccination. 
 
Future research 
The findings of our studies indicate that the positive associations between HPV types 
may be driven by increased HPV acquisition among men with prevalent HPV infections.  
However, the role of current HPV infections on the persistence of other types is not known.  
Many of the previous studies in women report increased HPV acquisition but not increased 
persistence by baseline infection status.  However, one study in men found multiple HPV 
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infections to be associated with both increased HPV acquisition and increased 
persistence[35].  There are many issues specific to the analysis of HPV persistence, such as 
specifying whether the outcome HPV type is a different baseline infection or a newly acquire 
type, since HPV persistence is shown to differ between prevalent and incident infections[44].  
In addition, a study recently showed the multiple clearance events within an individual are 
highly correlated[81]; thus, statistical methods need to appropriately account for the lack of 
independence between HPV infections.  Therefore, to extend the findings of the current study 
and better understand the natural history of multiple HPV infections in men, the next step 
will be to carry-out the analysis of HPV persistence among men with vaccine-relevant HPV 
types compared to men without these type infections at baseline.  We plan to do this 
complementary study using similar methods to paper two, including parametric frailty 
models, which account for the correlation between multiple HPV types.  
With the recent approval of HPV vaccination in men[66], these data fill an important 
gap in our knowledge on the distribution and associations between HPV types in multiple 
infections among men.  However, in the epidemiological current studies, we are not able to 
make inferences regarding the biological potential for HPV type competition.  In populations 
where negative associations between HPV types are observed, molecular studies and 
prospective studies of couples are needed to address whether these associations are likely due 
to biological competition between HPV types.  In addition, future surveillance studies in pre- 
and post-vaccinated populations are needed to monitor for changes in the HPV type 
distribution and assess the long-term potential for HPV type replacement at the population-
level. 
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Appendix Document 1 
PCR amplification protocol for HPV DA 
PCR amplification with GP5+ and biotinylated GP6+ primers, after a 4 minute denaturation 
step of 94˚C, 40 cycles total. Each cycle includes: 
  1.  denaturation step at 94˚C for 20 sec 
 2.  annealing step at 38˚C for 30 sec  
 3.  elongation step at 71˚C for 80 seconds (84), where the final elongation step will be 
prolonged for a further 4 minutes 
 
Each PCR run of 86 samples will include 2 negative sample preparation controls, 2 PCR 
negative controls, and a 100 pg to 10 ng dilution series of DNA of the HPV 16 containing 
cervical cancer cell line SiHa (containing 1 to 2 copies of HPV 16 per cell), the latter serving 
as positive controls.  
 
HPV specific PCR products will be detected by hybridisation in an EIA format with two 
pairs of cocktail probes (i.e. high-risk HPV and low-risk HPV), together representing the 36 
HPV types (84).  Apart from the PCR products of samples and positive and negative PCR 
controls, each EIA run containing 86 samples will include 2 EIA positive controls: 
biotinylated PCR products derived from cloned HPV 6 (for low-risk HPV cocktail probe) 
and cloned HPV 16 DNA (for high-risk HPV cocktail probe) plasmids, respectively, 
generating an optical density (OD) value at 405nm of about 0.6 ± 0.2 after overnight 
substrate incubation in the EIA procedure(84).  These EIA positive controls provide 
information about possible failure of the capturing, denaturation, hybridisation and staining 
steps used EIA procedures.  
 
A GP5+/6+ PCR run will be considered valid when (a) all negative controls give OD405nm 
values < 0.1, (b) the lowest concentration of positive PCR controls (i.e. SiHa-100 pg) gives 
an OD405nm value near or higher than the cut-off value, and the SiHa-1 ng control a value that 
is clearly higher than the cut-off when using the high-risk HPV cocktail probe, and (c) the 
EIA positive controls give an OD405nm value of >0.5.  If (c) is invalid all PCR products of that 
particular EIA run will be subjected to an additional EIA round with new reagents.  If (c) is 
valid but (a) and/or (b) not, the whole PCR procedure will be repeated with new PCR 
reagents.  The following equation will be used to determine the EIA cut-off value: cut-off = 3 
times the mean OD405nm value of the 4 negative controls.  Samples with an OD405nm equal to 
or greater than the cut-off are considered GP5+/6+ PCR positive. 
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Appendix Document 2 
SAS code for semi-Bayes logistic regression 
%macro SB_IND_models (out, out2, TYPE, B1MU=, B1TAU=, B2MU=, B2TAU=, B3MU=, B3TAU=, B4MU=, B4TAU=); 
ods graphics on; 
proc mcmc data=HPV_ONLY  
nbi=2000 nthin=10 ntu=2000 nmc=80000  
diag=(mcse ess) outpost=&out  seed=24610; 
ods select PostSummaries PostIntervals mcse ess TADpanel; 
    
ARRAY beta[*] beta0-beta4; 
ARRAY MU[*] MU1-MU4; 
parms beta0-beta4 = 0; 
parms MU1-MU4= 0; 
prior B1MU ~normal(0,var=0.5); 
prior B2MU ~normal(0,var=0.5); 
prior B3MU ~normal(0,var=0.5); 
prior B4MU ~normal(0,var=0.5); 
prior beta0 ~ normal(0, var=1e6); 
prior beta1 ~ normal(&B1MU, var =&B1TAU); 
prior beta2 ~ normal(&B2MU, var =&B2TAU); 
prior beta3 ~ normal(&B3MU, var =&B3TAU); 
prior beta4 ~ normal(&B4MU, var =&B4TAU); 
 
p = logistic(beta0+BETA1*OHPV6+BETA2*OHPV11+BETA3*OHPV16+BETA4*OHPV18); 
model &TYPE ~ binomial(n=1,p);  
run; 
 
data &out2;  
set &out; 
drop LogPrior LogLike LogPost; 
ARRAY beta[4] beta1-beta4; 
ARRAY betaOR[4] betaOR1-betaOR4; 
do i=1 to 4; 
betaOR[i]=exp(beta[i]) ; 
end; output;  
run; 
 
proc univariate data=&out2; 
var betaOR1-betaOR4; 
output out=&TYPE mean=betaOR1-betaOR4 pctlpts=2.5 97.5 pctlpre=betaOR1-betaOR4 pctlname=LCL UCL; 
run; 
 
proc print data=Pctls; run; 
 
proc freq; 
table   betaOR1*betaOR1LCL*betaOR1UCL 
 betaOR2*betaOR2LCL*betaOR2UCL 
 betaOR3*betaOR3LCL*betaOR3UCL 
 betaOR4*betaOR4LCL*betaOR4UCL/list nocum nofreq nopercent; run; 
ods graphics off; 
%mend SB_IND_models; 
 
*SB WITH INDIVIDUAL PRIORS MU=adjusted average, TAU2=0.169(5x); 
%SB_IND_models ( 
out=HPV26, out2=postHPV26, TYPE=OHPV26, B1MU=0.535, B1TAU=0.169, B2MU=0.637, B2TAU=0.169, 
B3MU=0.584, B3TAU=0.169, B4MU=1.116, B4TAU=0.169);
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Appendix Table 2 
Parametric survival models with and without frailty term and covariates 
  Any-HPV HR-HPV 
HR (95%CI) MSR (95%CI) HR (95%CI) MSR (95%CI) 
o frailty term, 
unadjusted 
HPV-16  1.2 (1.1, 1.4) 1.3 (1.1, 1.5) 1.2 (1.0, 1.5) 1.2 (1.0, 1.5) 
HPV-18 1.8 (1.4, 2.2) 1.8 (1.5, 2.3) 1.6 (1.2, 2.2) 1.6 (1.2, 2.3) 
HPV-31 1.4 (1.1, 1.7) 1.4 (1.1, 1.8) 1.5 (1.1, 2.0) 1.5 (1.1, 2.1) 
HPV-45 1.9 (1.6, 2.2) 2.0 (1.6, 2.4) 1.8 (1.4, 2.4) 1.9 (1.4, 2.5) 
HPV-6 1.6 (1.2, 1.9) 1.6 (1.3, 2.1) 1.3 (0.9, 1.8) 1.3 (0.9, 1.8) 
HPV-11 1.7 (1.3, 2.2) 1.8 (1.3, 2.4) 1.7 (1.2, 2.5) 1.8 (1.2, 2.7) 
o frailty, 
adjusted
a
  
HPV-16  1.2 (1.1, 1.4) 1.2 (1.1, 1.4) 1.2 (0.9, 1.5) 1.2 (0.9, 1.4) 
HPV-18 1.8 (1.5, 2.3) 1.8 (1.5, 2.3) 1.6 (1.2, 2.2) 1.6 (1.1, 2.2) 
HPV-31 1.4 (1.1, 1.8) 1.4 (1.1, 1.7) 1.6 (1.2, 2.1) 1.5 (1.1, 2.0) 
HPV-45 1.9 (1.6, 2.3) 1.9 (1.6, 2.3) 1.8 (1.4, 2.3) 1.8 (1.4, 2.3) 
HPV-6 1.4 (1.1, 1.7) 1.4 (1.1, 1.7) 1.2 (0.8, 1.7) 1.2 (0.8, 1.6) 
HPV-11 1.7 (1.3, 2.2) 1.7 (1.3, 2.2) 1.8 (1.3, 2.6) 1.8 (1.2, 2.5) 
Frailty models,  
Unadjusted 
HPV-16  1.2 (0.9, 1.6) 1.2 (0.9, 1.7) 1.2 (0.8, 1.6) 1.2 (0.8, 1.6) 
HPV-18 2.0 (1.3, 3.0) 2.1 (1.3, 3.2) 1.6 (1.0, 2.6) 1.6 (1.0, 2.6) 
HPV-31 1.5 (1.0, 2.3) 1.6 (1.0, 2.4) 1.6 (1.0, 2.4) 1.6 (1.0, 2.5) 
HPV-45 2.1 (1.4, 2.9) 2.2 (1.5, 3.1) 2.0 (1.3, 2.9) 2.0 (1.3, 3.0) 
HPV-6 1.5 (1.0, 2.3) 1.5 (1.0, 2.4) 1.3 (0.8, 2.1) 1.3 (0.8, 2.1) 
HPV-11 1.9 (1.1, 3.3) 2.0 (1.1, 3.5) 1.7 (0.9, 3.1) 1.7 (0.9, 3.1) 
Frailty models, 
adjusted
a
 
HPV-16  1.2 (0.9, 1.6) 1.2 (0.9, 1.7) 1.1 (0.8, 1.6) 1.1 (0.8, 1.6) 
HPV-18 2.1 (1.4, 3.3) 2.2 (1.4, 3.5) 1.7 (1.0, 2.7) 1.7 (1.0, 2.8) 
HPV-31 1.5 (1.0, 2.3) 1.6 (1.0, 2.4) 1.6 (1.0, 2.5) 1.6 (1.0, 2.6) 
HPV-45 2.0 (1.4, 2.8) 2.1 (1.4, 3.1) 1.8 (1.2, 2.7) 1.8 (1.2, 2.8) 
HPV-6 1.4 (0.9, 2.1) 1.4 (0.9, 2.2) 1.2 (0.8, 2.0) 1.2 (0.8, 2.0) 
HPV-11 1.8 (1.0, 3.1) 1.8 (1.0, 3.3) 1.6 (0.9, 2.9) 1.6 (0.9, 3.0) 
Abbreviations: HR-HPV (high-risk HPV); HR (hazard ratio); CI (confidence interval); MSR (median 
survival ratio) 
a
Adjusted for age, bathing frequency, number of sexual partners (in 6 months), consistent condom use (in 
6 months), C. trachomatis infection 
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Appendix Table 3 
Sensitivity analysis results for any-HPV acquisition comparing methods used to code 
missing data for time to event analysis  
Alternate interval coding:                                            
if HPV data was missing outside of 
the acquisition interval, assumed 
missing value was HPV positive 
Original interval coding:                                                
if HPV data was missing outside of 
the acquisition interval, assumed 
missing value was HPV negative 
aHR (95% CI)
 a,b
 aMSR (95%CI)
a,b
 aHR (95% CI)
 a,b
 aMSR  (95% CI)
 a,b
 
HPV-16  1.2 (1.0, 1.8) 1.2 (1.0, 1.7) 1.2 (0.9, 1.6) 1.2 (0.9, 1.7) 
HPV-18  2.0 (1.2, 3.3) 2.0 (1.2, 3.2) 2.1 (1.4, 3.3) 2.2 (1.4, 3.5) 
HPV-31  1.7 (1.0, 2.8) 1.6 (1.0, 2.6) 1.5 (1.0, 2.3) 1.6 (1.0, 2.4) 
HPV-45  2.0 (1.4, 2.9) 1.9 (1.3, 3.0) 2.0 (1.4, 2.8) 2.1 (1.4, 3.1) 
HPV-6  1.4 (0.9, 2.1) 1.4 (0.9, 2.1) 1.4 (0.9, 2.1) 1.4 (0.9, 2.2) 
HPV-11  1.9 (1.1, 3.1) 1.9 (1.0, 3.2) 1.8 (1.0, 3.1) 1.8 (1.0, 3.3) 
HPV-16, 18
c
 1.5 (1.2, 2.0) 1.5 (1.1, 1.9) 1.5 (1.2, 1.9) 1.5 (1.2, 2.0) 
HPV-6, 11
d
 1.5 (1.0, 2.2) 1.5 (1.0, 2.3) 1.5 (1.0, 2.1) 1.5 (1.0, 2.2) 
HPV-16, 18, 6, 11
e
 1.5 (1.2, 2.0) 1.5 (1.2, 1.9) 1.5 (1.2, 1.9) 1.5 (1.2, 1.9) 
Abbreviations: aHR (adjusted hazard ratio); CI (confidence interval); aMSR (adjusted median survival 
ratio) 
a
Parametric frailty models adjusted for age (centered at 20 years), bathing frequency, number of sexual 
partners (in 6 months), consistent condom use (in 6 months), C. trachomatis infection 
b
All other HPV types except exposure HPV type
 
c
Index group HPV-16 and/or 18 positive vs. referent group HPV-16 and 18 negative 
d
Index group HPV-6 and/or 11 positive vs. referent group HPV-6 and 11 negative 
e
Index group HPV-16, 18, 6, and/or 11 positive vs. referent group HPV-16, 18, 6, and 11 negative 
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Appendix Table 5 
Estimated odds ratios between the vaccine-preventable HPV types 16 and 18 and all 
other HPV types including HPV-6 and 11 
  
HPV-16 
aOR (95% CI)
a
 
HPV-18 
aOR (95% CI)
a
 
HPV-6 1.7 (1.1, 2.6) 1.9 (1.1, 3.1) 
HPV-11 2.0 (1.1, 3.2) 1.8 (0.9, 3.1) 
HPV-26 1.7 (0.8, 3.0) 4.3 (2.1, 7.6) 
HPV-30 1.7 (0.9, 2.9) 3.0 (1.5, 5.3) 
HPV-31 2.9 (1.9, 4.3) 2.8 (1.6, 4.4) 
HPV-32 1.7 (0.9, 3.0) 2.2 (1.1, 3.9) 
HPV-33 1.9 (1.0, 3.0) 2.5 (1.3, 4.4) 
HPV-34 2.0 (0.8, 4.0) 3.0 (1.2, 6.3) 
HPV-35 2.6 (1.7, 3.8) 1.9 (1.1, 3.1) 
HPV-39 2.1 (1.2, 3.5) 2.2 (1.1, 3.9) 
HPV-40 3.7 (2.4, 5.4) 2.2 (1.3, 3.5) 
HPV-42 2.1 (1.4, 3.1) 2.2 (1.3, 3.5) 
HPV-43 1.8 (1.1, 2.7) 2.3 (1.3, 3.6) 
HPV-44 2.0 (0.9, 4.2) 2.6 (1.1, 5.3) 
HPV-45 1.8 (1.1, 2.7) 2.9 (1.6, 4.6) 
HPV-51 2.3 (1.4, 3.4) 1.8 (1.0, 3.0) 
HPV-52 1.7 (1.1, 2.6) 2.3 (1.3, 3.7) 
HPV-53 2.6 (1.3, 4.5) 2.2 (1.0, 4.1) 
HPV-54 1.4 (0.7, 2.6) 2.5 (1.1, 4.7) 
HPV-55 1.5 (0.8, 2.6) 2.0 (1.0, 3.6) 
HPV-56 2.2 (1.5, 3.1) 1.8 (1.1, 2.9) 
HPV-57 2.1 (0.8, 4.3) 2.7 (1.1, 5.4) 
HPV-58 2.6 (1.7, 3.9) 2.2 (1.3, 3.6) 
HPV-59 2.4 (1.5, 3.6) 2.9 (1.6, 4.6) 
HPV-61 2.1 (0.8, 4.3) 2.7 (1.1, 5.4) 
HPV-64 2.0 (0.9, 4.2) 2.6 (1.1, 5.3) 
HPV-66 2.1 (1.3, 3.0) 2.3 (1.3, 3.6) 
HPV-67 2.4 (1.6, 3.5) 1.8 (1.0, 2.9) 
HPV-68 1.3 (0.6, 2.3) 2.1 (1.0, 3.7) 
HPV-69 2.5 (1.4, 4.2) 2.8 (1.4, 4.9) 
HPV-70 1.6 (0.9, 2.6) 1.7 (0.8, 3.0) 
HPV-71 2.1 (0.8, 4.3) 2.7 (1.1, 5.4) 
HPV-72 2.7 (1.3, 4.9) 2.6 (1.2, 4.8) 
HPV-73 2.2 (1.2, 3.6) 3.0 (1.6, 5.0) 
HPV-81  1.7 (1.0, 2.8) 2.4 (1.2, 4.0) 
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HPV-82 1.5 (0.7, 2.7) 2.3 (1.0, 4.4) 
HPV-83 1.8 (0.9, 3.0) 2.8 (1.4, 4.8) 
HPV-84 1.8 (0.8, 3.3) 2.2 (0.9, 4.2) 
HPV-85 2.0 (0.8, 3.9) 2.7 (1.2, 5.5) 
HPV-86 1.8 (0.9, 3.3) 3.1 (1.4, 5.9) 
HPV-89 1.8 (1.0, 2.9) 2.4 (1.2, 4.1) 
HPV-JC9710 1.8 (1.1, 2.7) 2.8 (1.6, 4.3) 
HPV-X  1.2 (0.8, 1.8) 1.7 (1.0, 2.7) 
Abbreviations: aOR (adjusted odds ratio); CI (confidence interval) 
a
Odds ratios for pair-wise associations are adjusted for age, travel to Nairobi (in 6 months), bathing 
frequency, number of sexual partner (in 6 months), consistent condom use (in 6 months), and current 
Gonorrhea and C. trachomatis infection
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Appendix Table 6 
Comparison of any-HPV acquisition results for HPV-positive restricted population 
compared to analysis of the full cohort  
  
Restricted population:  
HPV positive at least once during 
study period  
Unrestricted:  
Original, full cohort 
aHR (95% CI) a,b 
aMSR  (95% CI) 
a,b aHR (95% CI) a,b 
aMSR  (95% CI) 
a,b 
HPV-16  1.0 (0.8, 1.3) 1.0 (0.8, 1.3) 1.2 (0.9, 1.6) 1.2 (0.9, 1.7) 
HPV-18  1.7 (1.2, 2.5) 1.7 (1.2, 2.6) 2.1 (1.4, 3.3) 2.2 (1.4, 3.5) 
HPV-31  1.3 (0.9, 1.8) 1.3 (0.9, 1.9) 1.5 (1.0, 2.3) 1.6 (1.0, 2.4) 
HPV-45  1.6 (1.2, 2.2) 1.7 (1.2, 2.3) 2.0 (1.4, 2.8) 2.1 (1.4, 3.1) 
HPV-6  1.2 (0.8, 1.7) 1.2 (0.8, 1.8) 1.4 (0.9, 2.1) 1.4 (0.9, 2.2) 
HPV-11  1.4 (0.9, 2.4) 1.5 (0.9, 2.5) 1.8 (1.0, 3.1) 1.8 (1.0, 3.3) 
HPV-16, 18
c
 1.2 (1.0, 1.5) 1.2 (1.0, 1.5) 1.5 (1.2, 1.9) 1.5 (1.2, 2.0) 
HPV-6, 11
d
 1.3 (0.9, 1.7) 1.3 (0.9, 1.8) 1.5 (1.0, 2.1) 1.5 (1.0, 2.2) 
HPV-16, 18, 6, 11
e
 1.2 (1.0, 1.5) 1.2 (1.0, 1.5) 1.5 (1.2, 1.9) 1.5 (1.2, 1.9) 
Abbreviations: aHR (adjusted hazard ratio); CI (confidence interval); aMSR (adjusted median 
survival ratio) 
a
Parametric frailty models adjusted for age, bathing frequency, number of sexual partners (in 6 
months), consistent condom use (in 6 months), C. trachomatis infection 
b
All other HPV types except exposure HPV type
 
c
Index group HPV-16 and/or 18 positive vs. referent group HPV-16 and 18 negative 
d
Index group HPV-6 and/or 11 positive vs. referent group HPV-6 and 11 negative 
e
Index group HPV-16, 18, 6, and/or 11 positive vs. referent group HPV-16, 18, 6, and 11 negative 
 Distribution of single and multiple type infections in the 10 most prevalent HPV types 
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Appendix Figure 1 
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Appendix Figure 2 
Select diagnostic plots from PROC MCMC
 
HPV-45
HPV-52
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Appendix Figure 3 
Survival function curves for HR-HPV acquisition estimated by nonparametric (P) and 
parametric frailty (PF) survival models 
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